Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
  • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/06—Phosphorus compounds without P—C bonds
  • C07F9/08—Esters of oxyacids of phosphorus
  • C07F9/09—Esters of phosphoric acids

Definitions

• novel prodrug salts of selective aquaporin inhibitors e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their synthesis.
• novel prodrug salts are useful e.g., in the prophylaxis, treatment, and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as edema associated with glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as optic nerve edema, e.g., optic nerve edema consequent to microgravity and/or radiation exposure, as well as edema consequent to an invasive central nervous system procedure, e.g.,
• lactic acidosis due to hypoxia before the resuscitation period), as well as hyponatremia and excess fluid retention, ovarian hyperstimulation syndrome, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, neuromyelitis optica, and glioblastoma, as well as fibromyalgia, multiple sclerosis, and migraines.
• diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, neuromyelitis optica, and gli
• Aquaporins are cell membrane proteins that act as molecular water channels to mediate the flow of water in and out of the cells. While there is some degree of passive diffusion or osmosis of water across cell membranes, the rapid and selective transport of water in and out of cells involves aquaporins. These water channels selectively conduct water molecules in and out of the cell, while blocking the passage of ions and other solutes, thereby preserving the membrane potential of the cell. Aquaporins are found in virtually all life forms, from bacteria to plants to animals. In humans, they are found in cells throughout the body.
• Aquaporin inhibitors may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.
• diseases of water imbalance for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.
• R 1 , R 2 , R 3 , R 4 , and R 5 are independently H, halogen (e.g., CI or Br), Ci_4-alkyl, Ci_4-haloalkyl (e.g., -CF 3 ), or cyano;
• R 6 and R 7 is OH and the other is O Q + or both of R 6 and R 7 are O Q + ;
• each Q + is independently Na + , K + , HOR 8 NH 3 + , (HOR 8 ) 2 NH 2 + , or (HOR 8 ) 3 NH + ;
• each R 8 is independently Ci_ 4 -alkylene (e.g., -CH 2 -CH 2 -).
• R 6 and R 7 is OH and the other is O Q + or both of R 6 and R 7 are O Q + ;
• each Q + is independently K + , HOR 8 NH 3 + , (HOR 8 ) 2 NH 2 + , or (HOR 8 ) 3 NH + ;
• each R 8 is independently Ci_ 4 -alkylene (e.g., -CH 2 -CH 2 -).
• composition comprising a compound of Formula I, e.g., a compound of Formula II, and a pharmaceutically acceptable excipient.
• a compound of Formula I for the prophylaxis, treatment, and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as edema associated with glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as optic nerve edema, e.g., optic nerve edema consequent to microgravity and/or radiation exposure, as well as edema consequent to
• lactic acidosis due to hypoxia before the resuscitation period), as well as hyponatremia and excess fluid retention, ovarian hyperstimulation syndrome, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, neuromyelitis optica, and glioblastoma, as well as migraines.
• diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, neuromyelitis optica, and glioblastoma, as well as migraines.
• cerebral edema e.g. cerebral edema consequent to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, hypoxia (including general systemic hypoxia and hypoxia due to cardiac arrest), water intoxication, hepatic failure, hepatic
• encephalopathy diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, lupus cerebritis, cardiac arrest, microgravity and/or radiation exposure, or an invasive central nervous system procedure, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation or, e.g., spinal cord edema consequent to spinal cord trauma, e.g., spinal cord compression; or
• optic nerve edema e.g., optic nerve edema consequent to microgravity and/or radiation exposure
• retinal edema or hyponatremia or excessive fluid retention, e.g., consequent to heart failure (HF), liver cirrhosis, nephrotic disorder, syndrome of inappropriate antidiuretic hormone secretion (SIADH), or infertility treatment; or
• ischemia/reperfusion injury myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, neuromyelitis optica, or glioblastoma;
• a therapeutically effective amount of a compound of Formula I e.g., a compound of Formula II.
• R 30 , R 31 , R 32 , R 33 , and R 34 are independently H, halogen (e.g., CI or Br), Ci_ 4 -alkyl, Ci_ 4 -haloalkyl (e.g., -CF 3 ), or cyano; and
• R 3"5 and R 3 J 6 0 are independently protecting groups, e.g., wherein R 35 and R 36 are independently a protecting group comprising Si, S, N, and/or O, e.g., wherein R 35 and R 36 are independently a protecting group comprising an optionally substitututed cyclic or acyclic ether, an optionally substituted silyl (e.g., -Si(Ci_ 6 -alkyl) 3 , e.g., -Si(Ci_ 4 -alkyl) 3 , e.g., -Si(CH 3 ) 3 ), an optionally substituted silyl ether, an optionally substituted ester, an optionally substituted ketone, or an optionally substituted thioether, e.g., wherein R 35 and R 36 are independently -CH 2 OR, -CH 2 SR, -C(OCi_ 6 -alkyl)(R') 2 , -CH(R
• R 35 and R 36 are not both -CH 2 -C 6 H5.
• R 40 and R 41 are independently protecting groups, e.g., wherein R 40 and R 41 are independently a protecting group comprising Si, S, N, and/or O, e.g., wherein R 40 and R 41 are independently a protecting group comprising an optionally substitututed cyclic or acyclic ether, an optionally substituted silyl (e.g., -Si(Ci_ 6 -alkyl) 3 , e.g., -Si(Ci_4-alkyl) 3 , e.g., -Si(CH 3 ) 3 ), an optionally substituted silyl ether, an optionally substituted ester, an optionally substituted ketone, or an optionally substituted thioether, e.g., wherein R 40 and R 41 are independently -CH 2 OR, -CH 2 SR,
• each R is independently H, Ci_ 6 -alkyl (e.g., Ci_ 4 -alkyl), -CH 2 Si(R") 3 , -CH 2 -Aryl (e.g., phenyl), -Ci_ 6 - alkenyl, -CH 2 OSi(R") 3 , alkoxyalkyl, or -CH 2 CH 2 Si(R") 3 and each R" is independently Ci_ 6 -alkyl (e.g., Ci_4-alkyl) or aryl optionally substituted with alkoxy (e.g., -Ci_ 6 -alkoxy, e.g., -Ci_4-alkoxy), halogen, cyano, or aryl (e.
• R 41 and R 341 are not both -CH 2 -C 6 Hs.
• a process for synthesizing a compound of Formula I e.g., a compound of Formula II, comprising reacting a compound of Formula III and/or Formula XX.
• Figure 1 depicts results of aquaporin-4 (Figure 1A) and aquaporin-2 ( Figure IB) mediated cell volume change assay, and the inhibitory effect of 5-chloro-N-(3,5-dichlorophenyl)- 2-hydroxybenzamide (Compound 3) against these aquaporins.
• Figure 2 depicts specificity of 5-chloro-N-(3,5-dichlorophenyl)-2-hydroxybenzamide (Compound 3) towards AQP-1 , AQP-2, AQP-4-M1 , AQP-4-M23, and AQP-5.
• Figure 3 depicts a Hummel-Dryer style assay for [3H]-labeled N-(3,5- bis(trifluoromethyl)phenyl)-2-hydroxy-5-(trifluoromethyl)benzamide (Compound 4) binding to purified AQP4b.
• Figure 4 depicts percent survival curves for the water toxicity mouse model using 0.76 mg/kg N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (Compound 1).
• a time course of edema formation is shown comparing no drug vs. N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2- hydroxybenzamide (Compound 1) at 0.76 mg/kg.
• the first time point at 5.67 min coincides with the scan slice at the middle of the brain during the first post-injection scan. Other time points are placed in a similar manner.
• the data is fitted to a single exponential equation:
• Figure 6 depicts the calcein fluorescence end-point assay used for high throughput screening.
• Figure 7 depicts hit validation using the Cell Bursting Aquaporin Assay; inset shows the structure of 5-chloro-N-(3,5-dichlorophenyl)-2-hydroxybenzamide (Compound 3).
• Figure 8 depicts reduction in intracranial pressure (ICP) in the mouse water toxicity model with N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (Compound 1) at 0.76 mg/kg.
• Figure 9 depicts plasma and serum levels of N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro- 2-hydroxybenzamide (Compound 1) converted from 2- ⁇ [3,5- bis(trifluoromethyl)phenyl]carbamoyl ⁇ -4-chlorophenyl phosphate bis ethanolamine salt.
• Figure 10 depicts mouse middle cerebral artery occlusion (MCAo) model of ischemic stroke.
• Figure 11 depicts relative change in hemispheric brain volume in the mouse middle cerebral artery occlusion (MCAo) model.
• Figure 12 depicts neurological outcome following MCAo in mice treated with saline (no drug, ⁇ ) or Compound 5 (o) (2- ⁇ [3,5-bis(trifluoromethyl)phenyl]carbamoyl ⁇ -4-chlorophenyl phosphate disodium salt).
• AQP4 Aquaporin-4
• BBB blood-brain barrier
• AQP4 knockout mice without the APQ4 gene, have improved survival compared to wild-type mice in models of ischemic stroke, water toxicity, bacterial meningitis, and spinal cord compression.
• Cerebral edema CE may be generally divided into 2 major categories: vasogenic and cytotoxic.
• Vasogenic cerebral edema may occur when a breach in the BBB allows water and solutes to diffuse into the brain. It has been reported that AQP4-null mice have increased brain edema in a model of subarachnoid hemorrhage, suggesting that AQP4 may be required for the clearance of water collected in intercellular space. In contrast, cytotoxic cerebral edema may be initiated by ischemia which may result in reduced plasma osmolality rather than a disrupted BBB. Ischemia may lead to a drop in ATP levels, which is thought to slow the Na-K ATPase pump resulting in an uptake of Na + and CP through leakage pathways.
• the net effect may be a cellular osmotic imbalance, drawing H 2 0 into cells - astrocytes more so than neurons - and leading to increased ICP.
• Mouse models for ischemic stroke, water toxicity, bacterial meningitis, and spinal-cord compression fall into this category.
• AQP4-null mice have been reported to have reduced CE pointing to AQP4 as the central pathway for water movement into the brain during the formation of cytotoxic CE.
• cytotoxic and vasogenic edema are not sharply divided categories; an injury that initially causes cytotoxic edema may be followed later, e.g., within the next hours to days, by vasogenic edema. This may suggest different treatments for cerebral edema at different times.
• AQP4 inhibitors may be of further utility for certain ailments where control of AQP4- medited water movement may augment neuroexcitation (by alteration of neuronal potassium homeostasis) and prove beneficial by reducing neuronal excitation, for example ailments such as fibromyalgia, multiple sclerosis, migraines and seizures (in particular but not limited to seizures associated with epilepsy).
• Glioblastoma is a common and aggressive malignant primary brain tumor. Inhibition of AQP4 in U87 human gliobastoma cell lines induces apoptosis.
• Aquaporin-2 (AQP2) is the primary route of water movement at the collecting duct in the kidney. Blocking this water channel would lower water reabsorption without incurring electrolyte imbalances or interfering with vasopressin receptor-mediated signaling. Evidence that an AQP2 blocker would not produce electrolyte imbalances, and instead be an effective treatment for hyponatremia, comes from patients with diabetes insipidus who lack functional AQP2. They exhibit chronic aquaresis but - if normal hydration is maintained - do not demonstrate any other consequence of their long-term loss of AQP2 function. [0035] Certain aquaporin inhibitors are described in International Patent Application No.
• an IV infusion or IV bolus may be preferred.
• rapid achievement of therapeutically effective amounts of therapeutic agent may be important to a successful therapeutic outcome.
• a therapeutic agent with only a limited solubility in water and/or physiological media may make IV administration of the therapeutic agent challenging.
• novel prodrug salts of selective aquaporin inhibitors which may have improved solubility in aqueous and/or physiological media
• novel prodrug salts of N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide which may have improved solubility in aqueous and/or physiological media.
• a prodrug form is a derivative of an active ingredient which converts in the body to the active ingredient, e.g., a prodrug of N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2- hydroxybenzamide is a derivative of N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2- hydroxybenzamide which converts in the body to N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2- hydroxybenzamide.
• alkyl is a saturated hydrocarbon moiety, preferably having one to six carbon atoms, preferably having one to four carbon atoms, which may be linear or branched.
• a “Ci_4-alkyl” is an alkyl having one to four carbon atoms.
• alkylene is a saturated hydrocarbon moiety, preferably having one to six carbon atoms, preferably having one to four carbon atoms, which may be linear or branched and which has two points of attachment.
• a Ci_4-alkylene is an alkylene having from one to four carbon atoms.
• Ci-alkylene is methylene (-CH 2 -).
• halogen is F, CI, Br, or I.
• haloalkyl is a saturated hydrocarbon moiety, preferably having one to six carbon atoms, preferably having one to four carbon atoms, which may be linear or branched, and is mono-, di-, or tri-substituted with halogen.
• the halogens may be the same (e.g., dichloromethyl) or different (e.g., chlorofluoromethyl).
• a Ci_4- haloalkyl is a haloalkyl having from one to four carbon atoms.
• aryl is a mono or polycyclic (e.g., bicyclic) aromatic hydrocarbon, preferably phenyl, which may be optionally substituted, e.g., optionally substituted with one or more groups independently selected from Ci-6 alkyl (e.g., methyl), halogen (e.g., CI or F), Ci-6- haloalkyl (e.g., trifluoromethyl), hydroxy, and carboxy.
• aryl in addition to being substituted with the groups disclosed herein, is further substituted with an aryl or a heteroaryl to form, e.g., biphenyl or pyridylphenyl.
• heteroaryl is an mono or polycyclic (e.g., bicyclic) aromatic moiety wherein one or more of the atoms making up the aromatic ring is sulfur or nitrogen rather than carbon, e.g., pyridyl or thiadiazolyl, which may be optionally substituted, e.g., optionally substituted with one or more groups independently selected from Ci-6 alkyl (e.g., methyl), halogen (e.g., CI or F), Ci-6-haloalkyl (e.g., trifluoromethyl), hydroxy, and carboxy.
• Ci-6 alkyl e.g., methyl
• halogen e.g., CI or F
• Ci-6-haloalkyl e.g., trifluoromethyl
• hydroxy is -OH.
• patient includes human or non-human (i.e., animal) patient.
• non-human i.e., animal
• the term encompasses both human and nonhuman.
• the term encompasses nonhuman. In another embodiment, the term encompasses human.
• therapeutically effective amount refers to an amount effective, when administered to a human or non-human patient, to provide a therapeutic benefit such as amelioration of symptoms, slowing of disease progression, or prevention of disease.
• the specific dose of substance administered to obtain a therapeutic benefit will, of course, be determined by the particular circumstances surrounding the case, including, for example, the specific substance administered, the route of administration, the condition being treated, and the individual being treated.
• fairly rapid with respect to onset of action means that the time it takes after a compound is administered for a response to be observed is 30 minutes or less, for example 20 minutes or less, for example 15 minutes or less, for example 10 minutes or less, for example 5 minutes or less, for example 1 minute or less.
• sodium phosphate refers to sodium dihydrogen phosphate (NaH 2 P0 4 ), disodium hydrogen phosphate (Na 2 HP0 4 ), and trisodium phosphate (Na 3 P0 4 ).
• potassium dihydrogen phosphate KH 2 PO 4
• dipotassium hydrogen phosphate K 2 HP0 4
• tripotassium phosphate K 3 PO 4
• bolus refers to administration of a therapeutic agent in a single injection that lasts for a relatively short period of time, e.g., about 5 minutes or less, e.g., about 3 minutes or less. A bolus may rapidly deliver a therapeutically effective amount of the therapeutic agent to the blood.
• R 1 , ft 2 , R 3 , R 4 , and R 5 are independently H, halogen (e.g., CI or Br), Ci_ 4 -alkyl, Ci_ 4 -haloalkyl (e.g., -CF 3 ), or cyano;
• R 6 and R 7 is OH and the other is O Q + or both of R 6 and R 7 are O Q + ;
• each Q + is independently Na + , K + , HOR 8 NH 3 + , (HOR 8 ) 2 NH 2 + , or (HOR 8 ) 3 NH + , e.g., K + ,
• each R 8 is independently Ci_ 4 -alkylene (e.g., -CH 2 -CH 2 -).
• R 1 , R 2 , R 3 , R 4 , and R 5 are independently H, halogen (e.g., CI or Br), Ci_4-haloalkyl (e.g., -CF 3 ), or cyano.
• R 1 , R 2 , R 3 , R 4 , and R 5 are independently H, halogen (e.g., CI or Br), or Ci_ 4 -haloalkyl (e.g., -CF 3 ).
• R 1 , R 3 , and R 5 are independently halogen (e.g., CI or Br) and R 2 and R 4 are H.
• R 1 , R 3 , and R 5 are independently Ci_4-haloalkyl (e.g., -CF 3 ) and R 2 and R 4 are H.
• R 1 , R 3 , and R 5 are independently F, CI, Br, or -CF 3 and R 2 and R 4 are H.
• Formula I or 1.1-1.3 wherein R 1 is halogen (e.g., CI or Br), R 2 and R 4 are H, and R 3 and R 5 are independently Ci_4-haloalkyl (e.g., -CF 3 ).
• R 1 is halogen (e.g., CI or Br)
• R 2 and R 4 are H
• R 3 and R 5 are independently Ci_4-haloalkyl (e.g., -CF 3 ).
• R 1 , R 2 , R 3 , R 4 , and R 5 are independently H, halogen (e.g., CI or Br), or cyano.
• R 1 and R 2 are independently halogen (e.g., CI or Br), R 3 and R 5 are H, and R 4 is cyano.
• R 1 is halogen (e.g., CI or Br)
• R 2 and R 4 are H
• R 3 and R 5 are independently Ci_4-haloalkyl (e.g., -CF 3 )
• R 6 is OH
• R 7 is O Q + .
• R 1 is halogen (e.g., CI or Br)
• R 2 and R 4 are H
• R 3 and R 5 are independently Ci_4-haloalkyl (e.g., -CF 3 )
• both R 6 and R 7 are 0 QH + .
• R 6 and R 7 is OH and the other is O Q + or both of R 6 and R 7 are O Q + ;
• each Q + is independently K + , HOR 8 NH 3 + , (HOR 8 ) 2 NH 2 + , or (HOR 8 ) 3 NH + , e.g., HOR 8 NH 3 + ,
• each R 8 is independently Ci_4-alkylene (e.g., -CH 2 -CH 2 -).
• each Q + is independently HOR 8 NH 3 + , (HOR 8 ) 2 NH 2 + , or (HOR 8 ) 3 NH + .
• a pharmaceutical composition comprising a compound of Formula I, e.g., a compound of 1.1-1.52, and a pharmaceutically acceptable excipient.
• a pharmaceutical composition comprising a compound of Formula II, e.g., a compound of 2.1-2.26, and a pharmaceutically acceptable excipient.
• Method A of treating or controlling a disease or condition mediated by an aquaporin comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I, e.g., a compound of 1.1- 1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26.
• a compound of Formula I e.g., a compound of 1.1- 1.52
• a compound of Formula II e.g., a compound of 2.1-2.26.
• A.2 Method A or A.l wherein the condition to be treated or controlled is edema, e.g. edema of the brain or spinal cord, e.g., cerebral edema, e.g. cerebral edema consequent to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis or, e.g., spinal cord edema, e.g., spinal cord edema consequent to spinal cord trauma, e.g., spinal cord compression.
• A.3 Method A, A.1 , or A.2 further comprising a treatment selected from one or more of the following: optimal head and neck positioning to facilitate venous outflow, e.g. head elevation 30°; avoidance of dehydration; systemic hypotension;
• hypothermia maintenance of normothermia or hypothermia; aggressive measures; osmotherapy, e.g., using mannitol or hypertonic saline; hyperventilation;
• administration of aspirin administration of aspirin; administration of amantadine; intravenous thrombolysis (e.g. using rtPA); mechanical clot removal; angioplasty; and/or stents.
• Method A.2 wherein the patient is at elevated risk of cerebral edema, e.g., due to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
• cerebral edema e.g., due to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
• Method A or A.1 -A.4 wherein the condition to be treated or controlled is cerebral edema consequent to glioma.
• A.19 Method A or A.1 -A.4 wherein the condition to be treated or controlled is cerebral edema consequent to hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
• A.20 Method A or A.1-A.3 wherein the condition to be treated or controlled is cerebral edema consequent to an abscess.
• A.21 Method A or A.1-A.3 wherein the condition to be treated or controlled is cerebral edema consequent to eclampsia.
• A.23 Method A or A.1-A.3 wherein the condition to be treated or controlled is cerebral edema consequent to lupus cerebritis.
• A.24 Method A or A.1-A.3 wherein the condition to be treated or controlled is edema consequent to hypoxia e.g., general systemic hypoxia, e.g., hypoxia caused by an interruption of blood perfusion, for example wherein the edema is cerebral edema consequent to hypoxia caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain, or wherein the edema is cardiac edema consequent to cardiac ischemia or other interruption of blood flow to the heart.
• hypoxia e.g., general systemic hypoxia, e.g., hypoxia caused by an interruption of blood perfusion
• the edema is cerebral edema consequent to hypoxia caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain
• the edema is cardiac edema consequent to cardiac ischemia or other interruption of blood flow to the heart.
• A.25 Method A or A.1-A.3 wherein the condition to be treated or controlled is cerebral edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• A.26 Method A or A.1-A.3 wherein the condition to be treated or controlled is cerebral edema consequent to an invasive central nervous system procedure, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• an invasive central nervous system procedure e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• Method A.25 or A.26 wherein the patient is at elevated risk of edema, e.g., due to microgravity and/or radiation exposure, neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• edema e.g., due to microgravity and/or radiation exposure, neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• A.31 Method A, A.1 , or A.2 wherein the condition to be treated or controlled is spinal cord edema, e.g., spinal cord edema consequent to a spinal cord trauma, e.g., spinal cord compression.
• A.32 Method A.31 wherein the condition to be treated or controlled is spinal cord edema consequent to spinal cord compression.
• optic nerve edema e.g., optic nerve edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• A.36 Method A or A.1 wherein the condition to be treated or controlled is epilepsy.
• A.37 Method A or A.1 wherein the condition to be treated or controlled is retinal ischemia or other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration.
• Method A or A.1 wherein the condition to be treated or controlled is myocardial ischemia/reperfusion injury.
• hyponatremia or excessive fluid retention e.g., consequent to heart failure (HF), for example congestive heart failure, liver cirrhosis, nephrotic disorder, syndrome of inappropriate antidiuretic hormone secretion (SIADH), or infertility treatment.
• HF heart failure
• SIADH syndrome of inappropriate antidiuretic hormone secretion
• A.52 Method A, A.49, or A.51 further comprising one or more of restriction of dietary sodium, fluid and/or alcohol; and/or administration of one or more diuretics, vasopressin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, aldosterone inhibitors, angiotensin receptor blockers (ARBs), beta- adrenergic antagonists (beta-blockers), and/or digoxin.
• ACE angiotensin converting enzyme
• ARBs angiotensin receptor blockers
• beta-blockers beta- adrenergic antagonists
• Method A.54 wherein the compound of Formula I, e.g., the compound of 1.1- 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is administered by injection, e.g., subcutaneously, intramuscularly, intravenously, or intrathecally, e.g., a bolus injected subcutaneously, intramuscularly,
• A.56 Method A.55 wherein the compound of Formula I, e.g., the compound of 1.1- 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is administered intravenously, e.g., IV bolus and/or IV infusion, e.g., IV bolus followed by IV infusion.
• IV bolus and/or IV infusion e.g., IV bolus followed by IV infusion.
• A.57 Method A or A.1 - A.56 wherein the patient is human.
• Formula II e.g., the compound of 2.1-2.26, is fairly rapid.
• edema e.g. edema of the brain or spinal cord
• cerebral edema e.g. cerebral edema consequent to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, lupus cerebritis, cardiac arrest, microgravity and/or radiation exposure, or invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation or, e.g., optic nerve edema, e.g., optic nerve edema consequent to microgravity and
• Method B further comprising a treatment selected from one or more of the
• optimal head and neck positioning to facilitate venous outflow e.g. head elevation 30°; avoidance of dehydration; systemic hypotension; maintenance of normothermia or hypothermia; aggressive measures; osmotherapy, e.g., using mannitol or hypertonic saline; hyperventilation; therapeutic pressor therapy to enhance cerebral perfusion; administration of barbiturates to reduce cerebral metabolism (CM0 2 ); hemicraniectomy; administration of aspirin; administration of amantadine; intravenous thrombolysis (e.g. using rtPA); mechanical clot removal; angioplasty; and/or stents.
• osmotherapy e.g., using mannitol or hypertonic saline
• hyperventilation therapeutic pressor therapy to enhance cerebral perfusion
• hemicraniectomy administration of aspirin; administration of amantadine; intravenous thro
• B.2 Method B wherein the patient is at elevated risk of cerebral edema, e.g., due to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
• B.3 Method B wherein the patient has suffered a stroke, head injury, or spinal injury.
• B.4 Method B.3 wherein the patient has suffered a stroke, head injury or spinal injury within 12 hours, e.g. within 6 hours, preferably within 3 hours of commencing treatment.
• Method B wherein the patient is at elevated risk of suffering a stroke, head injury or spinal injury, e.g., in combat or in an athletic competition.
• Method B.20 Method B or B.1 wherein the condition to be treated or controlled is cerebral edema consequent to Creutzfeldt- Jakob disease.
• Method B or B.1 wherein the condition to be treated or controlled is cerebral edema consequent to lupus cerebritis.
• hypoxia e.g., general systemic hypoxia, e.g., hypoxia caused by an interruption of blood perfusion, for example wherein the edema is cerebral edema consequent to hypoxia caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain, or wherein the edema is cardiac edema consequent to cardiac ischemia or other interruption of blood flow to the heart.
• general systemic hypoxia e.g., hypoxia caused by an interruption of blood perfusion
• the edema is cerebral edema consequent to hypoxia caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain
• cardiac edema consequent to cardiac ischemia or other interruption of blood flow to the heart.
• Method B or B.1 wherein the condition to be treated or controlled is cerebral edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• cerebral edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• Method B.23 or B.24 wherein the patient is at elevated risk of edema, e.g., due to microgravity and/or radiation exposure, neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• edema e.g., due to microgravity and/or radiation exposure, neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• Method B wherein the condition to be treated or controlled is optic nerve edema, e.g., optic nerve edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• optic nerve edema e.g., optic nerve edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• Method B wherein the condition to be treated or controlled is pulmonary edema.
• subcutaneously, intramuscularly, intravenously, or intrathecally e.g., a bolus administered subcutaneously, intramuscularly, intravenously, or intrathecally.
• B.39 Method B or B.1-B.38 wherein the patient is human.
• B.40 Method B or B.1-B.39 wherein the onset of action after administration of the prodrug salt of an AQP4 inhibitor, e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is fairly rapid.
• an AQP4 inhibitor e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is fairly rapid.
• Method C of treating or controlling a condition selected from hyponatremia and excessive fluid retention, e.g., consequent to heart failure (HF), for example congestive heart failure, liver cirrhosis, nephrotic disorder, syndrome of inappropriate antidiuretic hormone secretion (SIADH), or infertility treatment, comprising administering a therapeutically effective amount of a prodrug salt of an inhibitor of AQP2, e.g., a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, to a patient in need thereof.
• HF heart failure
• SIADH syndrome of inappropriate antidiuretic hormone secretion
• Method C further comprising one or more of restriction of dietary sodium, fluid and/or alcohol; and/or administration of one or more diuretics, vasopressin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, aldosterone inhibitors, angiotensin receptor blockers (ARBs), beta-adrenergic antagonists (beta-blockers), and/or digoxin.
• ACE angiotensin converting enzyme
• ARBs angiotensin receptor blockers
• beta-blockers beta-adrenergic antagonists
• compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is administered parenterally.
• Method C.4 wherein the prodrug salt of an AQP2 inhibitor, e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is administered intravenously, e.g., IV bolus and/or IV infusion, e.g., IV bolus followed by IV infusion.
• an AQP2 inhibitor e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26
• IV bolus and/or IV infusion e.g., IV bolus followed by IV infusion.
• prodrug salt of an AQP2 inhibitor e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is fairly rapid.
• Method D of treating or controlling a condition selected from epilepsy, retinal ischemia or other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, neuromyelitis optica, glioblastoma, fibromyalgia, multiple sclerosis, and a migraine comprising administering a therapeutically effective amount of a prodrug salt of an inhibitor of AQP4, e.g., a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., the compound of 2.1-2.26, to a patient in need thereof.
• Method D wherein the condition to be treated or controlled is retinal ischemia or other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration.
• Method D wherein the condition to be treated or controlled is congestive heart failure.
• Method D wherein the condition to be treated or controlled is glioblastoma.
• Method D wherein the condition to be treated or controlled is fibromyalgia.
• Method D wherein the condition to be treated or controlled is multiple sclerosis.
• an AQP4 inhibitor e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26
• Method D.15 wherein the prodrug salt of an AQP4 inhibitor, e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is administered intravenously, e.g., IV bolus and/or IV infusion, e.g., IV bolus followed by IV infusion.
• an AQP4 inhibitor e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26
• IV bolus and/or IV infusion e.g., IV bolus followed by IV infusion.
• Method E of treating or controlling a disease or condition mediated by an aquaporin comprising administering to a patient in need thereof a prodrug salt of the aquaporin inhibitor, e.g., a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, in an amount effective to inhibit the aquaporin.
• a prodrug salt of the aquaporin inhibitor e.g., a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26
• E.2 Method E or E.l wherein the condition to be treated or controlled is selected from edema, e.g. edema of the brain or spinal cord, e.g., cerebral edema, e.g. cerebral edema consequent to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis or, e.g., spinal cord edema, e.g., spinal cord edema consequent to spinal cord trauma, e.g., spinal cord compression.
• edema e.g. edema of the brain or spinal cord
• cerebral edema e.g. cerebral edema consequent to head trauma
• ischemic stroke e.g. cerebral edema consequent to head trauma
• ischemic stroke e.g. cerebral edema
• E.3 Method E, E.1 , or E.2 further comprising a treatment selected from one or more of the following: optimal head and neck positioning to facilitate venous outflow, e.g. head elevation 30°; avoidance of dehydration; systemic hypotension;
• hypothermia maintenance of normothermia or hypothermia; aggressive measures; osmotherapy, e.g., using mannitol or hypertonic saline; hyperventilation;
• administration of aspirin administration of aspirin; administration of amantadine; intravenous thrombolysis (e.g. using rtPA); mechanical clot removal; angioplasty; and/or stents.
• Method E.2 wherein the patient is at elevated risk of cerebral edema, e.g., due to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
• cerebral edema e.g., due to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
• Method E.5 wherein the patient has suffered a stroke, head injury or spinal injury within 12 hours, e.g. within 6 hours, preferably within 3 hours of commencing treatment.
• E.24 Method E or E.1-E.3 wherein the condition to be treated or controlled is edema consequent to hypoxia e.g., general systemic hypoxia, e.g., hypoxia caused by an interruption of blood perfusion, for example wherein the edema is cerebral edema consequent to hypoxia caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain, or wherein the edema is cardiac edema consequent to cardiac ischemia or other interruption of blood flow to the heart.
• hypoxia e.g., general systemic hypoxia, e.g., hypoxia caused by an interruption of blood perfusion
• the edema is cerebral edema consequent to hypoxia caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain
• the edema is cardiac edema consequent to cardiac ischemia or other interruption of blood flow to the heart.
• E.26 Method E or E.1-E.3 wherein the condition to be treated or controlled is cerebral edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• cerebral edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• Method E.25 or E.26 wherein the patient is at elevated risk of edema, e.g., due to microgravity and/or radiation exposure, neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• edema e.g., due to microgravity and/or radiation exposure, neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• Method E, E.1 , or E.2 wherein the condition to be treated or controlled is spinal cord edema, e.g., spinal cord edema consequent to spinal cord trauma, e.g., spinal cord compression.
• spinal cord edema e.g., spinal cord edema consequent to spinal cord trauma, e.g., spinal cord compression.
• E.33 Method E, E.1 , or E.2 wherein the condition to be treated or controlled is optic nerve edema, e.g., optic nerve edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• optic nerve edema e.g., optic nerve edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• ischemia or other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration.
• HF heart failure
• SIADH syndrome of inappropriate antidiuretic hormone secretion
• Method E, E.49, or E.50 further comprising one or more of restriction of dietary sodium, fluid and/or alcohol; and/or administration of one or more diuretics, vasopressin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, aldosterone inhibitors, angiotensin receptor blockers (ARBs), beta- adrenergic antagonists (beta-blockers), and/or digoxin.
• ACE angiotensin converting enzyme
• ARBs angiotensin receptor blockers
• beta-blockers beta- adrenergic antagonists
• compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is administered by injection, e.g., subcutaneously, intramuscularly, intravenously, or intrathecally, e.g., a bolus injected subcutaneously, intramuscularly, intravenously, or intrathecally.
• compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is administered intravenously, e.g., IV bolus and/or IV infusion, e.g., IV bolus followed by IV infusion.
• Method F of inhibiting an aquaporin in vivo comprising administering a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, in an amount effective to inhibit the aquaporin.
• a compound of Formula I e.g., a compound of 1.1-1.52
• a compound of Formula II e.g., a compound of 2.1-2.26
• the compound of Formula II e.g., the compound of 2.1-2.26
• IV bolus and/or IV infusion e.g., IV bolus followed by IV infusion.
• Method G to inhibit an aquaporin in a patient suffering from a disease or condition mediated by an aquaporin comprising administering an effective amount of a prodrug salt of an inhibitor of the aquaporin, e.g., a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, to inhibit the aquaporin.
• a prodrug salt of an inhibitor of the aquaporin e.g., a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26
• G.2 Method G or G.l wherein the condition to be treated or controlled is edema, e.g. edema of the brain or spinal cord, e.g., cerebral edema, e.g. cerebral edema consequent to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis or, e.g., spinal cord edema, e.g., spinal cord edema consequent to spinal cord trauma, e.g., spinal cord compression.
• edema e.g. edema of the brain or spinal cord
• cerebral edema e.g. cerebral edema consequent to head trauma
• ischemic stroke e.g. cerebral edema consequent to head trauma
• ischemic stroke e.g. cerebral edema
• meningitis
• G.3 Method G, G.l, or G.2 further comprising a treatment selected from one or more of the following: optimal head and neck positioning to facilitate venous outflow, e.g. head elevation 30°; avoidance of dehydration; systemic hypotension;
• osmotherapy e.g., using mannitol or hypertonic saline; hyperventilation;
• administration of aspirin administration of aspirin; administration of amantadine; intravenous thrombolysis (e.g. using rtPA); mechanical clot removal; angioplasty; and/or stents.
• Method G.2 wherein the patient is at elevated risk of cerebral edema, e.g., due to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
• cerebral edema e.g., due to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, water intoxication, hepatic failure, hepatic encephalopathy, or diabetic ketoacidosis.
• Method G.5 wherein the patient has suffered a stroke, head injury or spinal injury within 12 hours, e.g. within 6 hours, preferably within 3 hours of commencing treatment.
• G.24 Method G or G.1-G.3 wherein the condition to be treated or controlled is edema consequent to hypoxia, e.g., general systemic hypoxia, e.g., hypoxia caused by an interruption of blood perfusion, for example wherein the edema is cerebral edema consequent to hypoxia caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain, or wherein the edema is cardiac edema consequent to cardiac ischemia or other interruption of blood flow to the heart.
• hypoxia e.g., general systemic hypoxia, e.g., hypoxia caused by an interruption of blood perfusion
• the edema is cerebral edema consequent to hypoxia caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain
• the edema is cardiac edema consequent to cardiac ischemia or other interruption of blood flow to the heart.
• G.25 Method G or G.1-G.3 wherein the condition to be treated or controlled is cerebral edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• G.26 Method G or G.1-G.3 wherein the condition to be treated or controlled is cerebral edema consequent to an invasive central nervous system procedure, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• an invasive central nervous system procedure e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• Method G.25 or G.26 wherein the patient is at elevated risk of edema, e.g., due to microgravity and/or radiation exposure, neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• edema e.g., due to microgravity and/or radiation exposure, neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation.
• G.30 Method G, G.1-G.19, or G.24 wherein the edema is cytotoxic cerebral edema or is primarily cytotoxic cerebral edema.
• Method G, G.1 , or G.2 wherein the condition to be treated or controlled is spinal cord edema, e.g., spinal cord edema consequent to a spinal cord trauma, e.g., spinal cord compression.
• spinal cord edema e.g., spinal cord edema consequent to a spinal cord trauma, e.g., spinal cord compression.
• G.33 Method G, G.1 , or G.2 wherein the condition to be treated or controlled is optic nerve edema, e.g., optic nerve edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• optic nerve edema e.g., optic nerve edema consequent to microgravity and/or radiation exposure, e.g., exposure from space flight or from working with radioactive materials or from working in radioactive areas.
• G.34 Method G, G.1 , or G.2 wherein the condition to be treated or controlled is retinal edema.
• G.36 Method G or G.l wherein the condition to be treated or controlled is epilepsy.
• G.37 Method G or G.1 wherein the condition to be treated or controlled is retinal ischemia or other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration.
• hyponatremia or excessive fluid retention e.g., consequent to heart failure (HF), for example congestive heart failure, liver cirrhosis, nephrotic disorder, syndrome of inappropriate antidiuretic hormone secretion (SIADH), or infertility treatment.
• HF heart failure
• SIADH syndrome of inappropriate antidiuretic hormone secretion
• G.51 Method G, G.49, or G.50 wherein the condition to be treated or controlled is ovarian hyperstimulation syndrome.
• G.52 Method G, G.49, or G.50 further comprising one or more of restriction of dietary sodium, fluid and/or alcohol; and/or administration of one or more diuretics, vasopressin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, aldosterone inhibitors, angiotensin receptor blockers (ARBs), beta- adrenergic antagonists (beta-blockers), and/or digoxin.
• ACE angiotensin converting enzyme
• ARBs angiotensin receptor blockers
• beta-blockers beta- adrenergic antagonists
• Method G.54 wherein the prodrug salt of an inhibitor of the aquaporin, e.g., the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is administered by injection, e.g., subcutaneously, intramuscularly, intravenously, or intrathecally, e.g., a bolus injected subcutaneously, intramuscularly, intravenously, or intrathecally.
• injection e.g., subcutaneously, intramuscularly, intravenously, or intrathecally, e.g., a bolus injected subcutaneously, intramuscularly, intravenously, or intrathecally.
• a compound of Formula I e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, for use in treating or controlling a disease or condition mediated by an aquaporin.
• a compound of Formula I e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, for use in any of Methods A, e.g., A.1-A.58, any of Methods B, e.g., B.1-B.41, any of Methods C, e.g., C.1-C.8, any of Methods D, e.g., D.1-D.19, any of Methods E, e.g., E.1-E.59, any of Methods F, e.g., F.l- F.5, and any of Methods G, e.g., G.1-G.58.
• Methods A e.g., A.1-A.58
• any of Methods B e.g., B.1-B.41
• any of Methods C e.g., C.1-C.8
• a compound of Formula I e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, in the manufacture of a medicament for treating or controlling a disease or condition mediated by an aquaporin.
• a compound of Formula I e.g., a compound of
• Methods A e.g., A.1-A.58, any of Methods B, e.g., B.1-B.41, any of Methods C, e.g, C.1-C.8, any of Methods D, e.g., D.1-D.19, any of Methods E, e.g., E.1-E.59, any of Methods F, e.g., F.1-F.5, and any of Methods G, e.g., G.1-G.58.
• a pharmaceutical composition comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, in combination with a pharmaceutically acceptable excipient for use in treating or controlling a disease or condition mediated by an aquaporin.
• a pharmaceutical composition comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, in combination with a pharmaceutically acceptable excipient for use in any of Methods A, e.g., A.1-A.58, any of Methods B, e.g., B.1-B.41, any of Methods C, e.g., C.1-C.8, any of Methods D, e.g., D.1-D.19, any of Methods E, e.g., E.1-E.59, any of Methods F, e.g., F.1-F.5, and any of Methods G, e.g., G.1-G.58.
• a pharmaceutically acceptable excipient for use in any of Methods A, e.g., A.1-A.58, any of Methods B, e.g
• glioma e.g., glioblastoma
• meningitis acute mountain sickness, infection, metabolic disorder, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, lupus cerebritis, optic nerve edema, hyponatremia, fluid retention, ovarian hyperstimulation syndrome, epilepsy, retinal ischemia or other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial in
• a dose or method of administration of the dose of the present disclosure is not particularly limited. Dosages employed in practicing the present disclosure will of course vary depending, e.g. on the particular disease or condition to be treated, the particular compound used, the mode of administration, and the therapy desired.
• the compounds may be administered by any suitable route, including orally, parenterally, transdermally, or by inhalation. In stroke or other severely debilitating diseases or conditions, for example where the patient may be unconscious or unable to swallow, an IV infusion and/or IV bolus may be preferred. In general, satisfactory results, e.g. for the treatment of diseases as hereinbefore set forth are indicated to be obtained on oral administration at dosages of the order from about 0.01 to 15.0 mg/kg.
• an indicated daily dosage for oral administration will accordingly be in the range of from about 0.75 to 1000 mg per day, conveniently administered once, or in divided doses 2 to 3 times, daily or in sustained release form.
• Unit dosage forms for oral administration thus for example may comprise from about 0.2 to 75 or 150 mg, e.g. from about 0.2 or 2.0 mg to 50, 75, 100, 125, 150 or 200 mg of a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, together with a pharmaceutically acceptable diluent or carrier therefor.
• the dose may be 0.1 or 0.25 mg to 500 mg per day, e.g., from about 0.25 to 75 or 150 mg, e.g., from about 0.1 or 0.25 or 2.0 mg to 50, 75, 100, 125, 150, 200, 300, 400, or 500 mg, by bolus or if IV by bolus or infusion.
• composition I a pharmaceutical composition
• a pharmaceutical composition comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, and a pharmaceutically acceptable excipient.
• Composition I as follows:
• composition I wherein the composition comprises 0.1 or 0.25 mg to 2.0 g of the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, e.g., from about 0.1 or 0.25 mg to 75 mg or 600 mg, e.g., from about 0.1 or 0.25 or 1 or 2 mg or 5 or 10 or 15 or 20 to 50, 75, 100, 125, 150, 200, 300, 400, 500, or 600 mg, or 1 g, 1.5 g, or 2.0 g, e.g., from about 5 to 50, 75, 100, 125, 150, 200, 300, 400, 500, or 600 mg, or 1 g, 1.5 g, or 2 g, e.g., from about 5 to 500 mg, e.g., from about 5 to 300 mg, e.g., from about 5 to 200 mg, e.g., from about 25 to 500 mg, e
• composition I wherein the composition comprises 2- ⁇ [3,5- bis(trifluoromethyl)phenyl]carbamoyl ⁇ -4-chlorophenyl dihydrogen phosphate in an amount sufficient to provide a dose of 0.01 or 0.1 or 0.5 mg/kg to 1 or 5 or 10 or 15 mg/kg of N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide, e.g., a dose of about 0.05 to 1 or 5 mg/kg, e.g., a dose of about 0.05 to 0.1, 0.2, 0.3, 0.4, 0.5, 1, 5, 10 or 20 mg/kg, e.g., a dose of about 0.5 to 1, 2, 3, 4, 5 or 10 or 20 mg/kg, e.g, a dose of about 1 to 2, 3, 4, 5, 10, 20 or 50 mg/kg.
• a dose of about 0.05 to 1 or 5 mg/kg e.g., a dose of about 0.05 to 0.1, 0.2
• composition I 1.1, or 1.2 wherein the pharmaceutically acceptable excipient comprises one or more buffering agents which may control pH, e.g., one or more of sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4 ), potassium phosphate (e.g., KH 2 P0 4 and/or K 2 HP0 4 ),
• buffering agents which may control pH, e.g., one or more of sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4 ), potassium phosphate (e.g., KH 2 P0 4 and/or K 2 HP0 4 ),
• tris(hydroxymethyl)aminomethane also known as tris base
• tris(hydroxymethyl)aminomethane acetate also known as tris acetate
• zinc chloride meglumine
• sodium acetate potassium acetate
• sodium hydroxide sodium hydroxide
• arginine e.g., one or more of sodium citrate, Na 2 HP0 4 ,
• tris(hydroxymethyl)aminomethane tris(hydroxymethyl)aminomethane acetate e.g., Na 2 HP0 4 , e.g., tris(hydroxymethyl)aminomethane, e.g.,
• composition I or 1.1-1.3 wherein the composition comprises 1 or 5 mg to 200 or 500 mg of one or more buffering agents, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
• buffering agents e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
• composition I or 1.1-1.4 wherein the composition comprises one or more of sodium citrate and sodium phosphate, e.g., Na 2 HP0 4 .
• composition I or 1.1-1.5 wherein the composition comprises sodium citrate.
• Composition 1.8 wherein the composition comprises 1 or 5 mg to 200 or 500 mg sodium phosphate, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium phosphate, e.g., Na 2 HP0 4 .
• composition 1.10 wherein the composition comprises 1 or 5 mg to 200 mg or 500 mg Na 2 HP0 4 , e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg Na 2 HP0 4 .
• composition I or 1.1-1.11 wherein the composition comprises one or more bulking agents which may provide an adequate structure to the lyophilized cake, e.g., one or more of mannitol, lactose, sucrose, trehalose, sorbitol, glucose, raffinose, arginine, glycine, histidine, dextran (e.g., dextran 40),
• one or more bulking agents which may provide an adequate structure to the lyophilized cake, e.g., one or more of mannitol, lactose, sucrose, trehalose, sorbitol, glucose, raffinose, arginine, glycine, histidine, dextran (e.g., dextran 40),
• composition I or 1.1-1.12 wherein the composition comprises 5 or 10 or 50 mg to 2 or 5 g of one or more bulking agents, e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g of one or more bulking agents.
• dextran e.g., dextran 40
• composition 1.14 wherein the composition comprises 5 or 10 or 50 mg to 2 or 5 g dextran (e.g., dextran 40), e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g dextran (e.g., dextran 40).
• dextran e.g., dextran 40
• dextran 40 e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g dextran (e.g., dextran 40).
• composition I or 1.1-1.15 wherein the composition comprises one or more solubilizing agents, e.g., ethylenediamine tetraacetic acid (EDTA) or a salt thereof (e.g., calcium disodium EDTA, disodium EDTA, sodium EDTA), alpha cyclodextrin, hydroxypropyl- -cyclodextrin, polysorbate 80, tert-butanol, isopropanol, dichloromethane, ethanol, acetone, and glycerol; one or more collapse temperature modifiers which may shift the overall collapse temperature higher, e.g., one or more of dextran, Ficoll ® , gelatin, and hydroxyethyl starch; one or more tonicity modifiers, e.g., one or more of sodium chloride, potassium chloride, sucrose, mannitol, glucose, and lactose; and one or more antimicrobial agents, e.g., one or more of
• composition I or 1.1-1.16 wherein the composition is a solid.
• composition I or 1.1-1.17 wherein the composition is lyophilized.
• Composition I or 1.1-1.18 wherein the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is lyophilized, e.g., by freezing, primary drying, and secondary drying.
• Composition 1.19 wherein the compound of Formula I, e.g., the compound of 1.1- 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is lyophilized, e.g., by freezing, primary drying, and secondary drying, prior to admixture with the pharmaceutically acceptable excipient.
• Composition I or 1.1-1.22 which is suitable for constitution, or reconstitution if lyophilized, with a solvent into a pharmaceutically acceptable liquid (e.g., a solution or suspension, e.g., a solution).
• a pharmaceutically acceptable liquid e.g., a solution or suspension, e.g., a solution.
• composition I or 1.1-1.23 wherein the composition is admixed with a solvent, e.g., a sterile solution, e.g., sterile water for injection, a sterile solution comprising dextrose (e.g., dextrose injection 5%), a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection), a sterile solution comprising benzyl alcohol (e.g., bacteriostatic water for injection with benzyl alcohol or bacteriostatic sodium chloride for injection with benzyl alcohol), or Lactated Ringer's.
• a solvent e.g., a sterile solution, e.g., sterile water for injection, a sterile solution comprising dextrose (e.g., dextrose injection 5%), a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection), a sterile solution comprising benzyl alcohol (e.
• composition I or 1.1 - 1.24 wherein the composition is admixed with 0.5 to 500 mL solvent, e.g., from about 1 or 2 mL to 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, 150, 200, 300 or 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• solvent e.g., from about 1 or 2 mL to 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• composition I or 1.1 - 1.25 wherein the composition is admixed with 0.5 to 500 mL sterile solution, e.g., sterile water for injection, a sterile solution comprising dextrose (e.g., dextrose injection 5%), a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection), a sterile solution comprising benzyl alcohol (e.g., bacteriostatic water for injection with benzyl alcohol or bacteriostatic sodium chloride for injection with benzyl alcohol), or Lactated Ringer's, e.g., from about 1 or 2 mL to 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, 150, 200, 300 or 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100
• composition I or 1.1-1.27 wherein the composition is admixed with sterile water for injection.
• composition 1.28 wherein the composition is admixed with 0.5 to 500 mL sterile water for injection, e.g., from about 1 or 2 mL to 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, 150, 200, 300 or 500 mL, e.g., from about 1 or 2 to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• Composition I or 1.1 - 1.29 wherein the composition is admixed with a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection).
• Composition 1.30 wherein the composition is admixed with 0.5 to 500 mL a sterile solution comprising sodium chloride (e.g., 0.9%> sodium chloride injection), e.g., from about 1 of 2 mL to 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, 150, 200, 300 or 500 mL, e.g., from about 1 or 2 to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• sodium chloride e.g. 0.9%> sodium chloride injection
• a buffering agent e.g., one or more of sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4
• composition 1.32 wherein the solvent, e.g., the sterile solution, comprises 1 or 5 mg to 200 or 500 mg of one or more buffering agents, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
• the solvent e.g., the sterile solution
• the buffering agents e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
• composition 1.32-1.34 wherein the solvent, e.g. the sterile solution comprises sodium citrate.
• Composition 1.35 wherein the solvent, e.g., the sterile solution, comprises 1 or 5 mg to 200 or 500 mg sodium citrate, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium citrate.
• the solvent e.g., the sterile solution
• sodium phosphate e.g., Na 2 HP04.
• composition 1.37 wherein the solvent, e.g., the sterile solution, comprises 1 or 5 mg to 200 mg or 500 mg sodium phosphate, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium phosphate, e.g., Na 2 HP0 4 .
• the solvent e.g., the sterile solution
• comprises 1 or 5 mg to 200 mg or 500 mg sodium phosphate e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium phosphate, e.g., Na 2 HP0 4 .
• the solvent e.g., the sterile solution comprises one or more bulking agents, e.g., one or more of maltose, mannose, ribose, cyclodextrin, mannitol, lactose, sucrose, trehalose, sorbitol, glucose, raffmose, arginine, glycine, histidine, dextran (e.g., dextran 40), polyvinylpyrrolidone, polyethylene glycol, and polypropylene glycol, e.g., one or more of mannitol, glucose, sucrose, lactose, trehalose, and dextran (e.g., dextran 40).
• the solvent e.g., the sterile solution comprises one or more bulking agents, e.g., one or more of maltose, mannose, ribose, cyclodextrin, mannitol, lactose, sucrose, tre
• composition 1.24-1.39 wherein the solvent, e.g., the sterile solution, comprises 5 or 10 or 50 mg to 2 or 5 g of one or more bulking agents, e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g of one or more bulking agents.
• the solvent e.g., the sterile solution
• the bulking agents e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g of one or more bulking agents.
• composition 1.24-1.40 wherein the solvent, e.g., the sterile solution, comprises dextran (e.g., dextran 40).
• the solvent e.g., the sterile solution
• dextran e.g., dextran 40
• composition 1.41 wherein the solvent, e.g. the sterile solution, comprises 5 or 10 or 50 mg to 2 or 5 g dextran (e.g., dextran 40), e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 dextran (e.g., dextran 40).
• dextran e.g., dextran 40
• composition 1.24-1.42 wherein the solvent, e.g., the sterile solution, comprises one or more solubilizing agents, e.g., ethylenediamine tetraacetic acid (EDTA) or a salt thereof (e.g., calcium disodium EDTA, disodium EDTA, sodium EDTA), alpha cyclodextrin, hydroxypropyl- -cyclodextrin, polysorbate 80, tert-butanol, isopropanol, dichloromethane, ethanol, acetone, and glycerol; one or more collapse temperature modifiers which may shift the overall collapse temperature higher, e.g., one or more of dextran, Ficoll ® , gelatin, and hydroxyethyl starch; one or more tonicity modifiers, e.g., one or more of sodium chloride, potassium chloride, sucrose, mannitol, and glucose; and one or more antimicrobial agents, e.g
• Composition 1.24-1.43 wherein the pH is between pH 7 and pH 10.5, e.g., between pH 7 and pH 9.5, e.g., between pH 7 and pH 8.
• composition 1.24-1.44 wherein the composition is filtered to remove particles and microbes, e.g., filtered prior to injection.
• composition 1.24-1.45 wherein the compositions is administered about 24 hours, 12 hours, 10 hours, 8 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 3 minutes, 2 minutes or 1 minute or less after admixture.
• Composition I or 1.1 - 1.46 wherein the composition is for injection, e.g., subcutaneously, intramuscularly, intravenously, or intrathecally, e.g.,
• intramuscularly or intravenously e.g., a bolus injected subcutaneously, intramuscularly, intravenously, or intrathecally.
• composition 1.47 wherein the composition is for injection intravenously, e.g., IV bolus and/or IV infusion, e.g., IV bolus followed by IV infusion.
• composition 1.47 wherein the composition is for injection intramuscularly, e.g., IM bolus and/or IM infusion, e.g., IM bolus followed by IM infusion.
• the infusion e.g., IV or IM
• composition I wherein the composition is formulated for oral administration.
• Composition 1.51 wherein the composition is a tablet, capsule, solution, suspension, or the like.
• abnormalities in intraocular pressure and/or tissue hydration myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, neuromyelitis optica, or migraines.
• composition I or 1.1 -1.53 wherein the composition comprises one or more additional therapeutic agents, e.g., one or more additional therapeutic agents for pulmonary edema, fibromyalgia, or multiple sclerosis.
• additional therapeutic agents e.g., one or more additional therapeutic agents for pulmonary edema, fibromyalgia, or multiple sclerosis.
• Composition I or 1.1-1.54 wherein the composition is administered concurrently or sequentially, in either order, with one or more additional therapeutic agents, e.g., one or more additional therapeutic agents for cerebral edema, stroke, traumatic brain injury, glioma (e.g., glioblastoma), meningitis, acute mountain sickness, infection, metabolic disorder, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, lupus cerebritis, optic nerve edema, hyponatremia, fluid retention, ovarian hyperstimulation syndrome, epilepsy, retinal ischemia or other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure
• composition I or 1.1-1.55 wherein the composition is administered concurrently or sequentially, in either order, with one or more additional therapeutic agents, e.g., one or more additional therapeutic agents for pulmonary edema,
• composition I or 1.1 - 1.57 wherein the composition for use in any of the methods described herein, e.g., for use in Method A, e.g., Method A.1-A.58, for use in Method B, e.g., Method B.1-B.41, e.g., for use in Method C, e.g., C.1-C.8, e.g., for use in Method D, e.g., D.1-D.19, e.g., for use in Method E, e.g., E.1-E.59, e.g., for use in Method F, e.g., F.1-F.5, e.g., for use in Method G, e.g., G.1-G.58..
• the compound of Formula I e.g., the compound of 1.1-1.52
• the compound of Formula II e.g., the compound of 2.1-2.26
• a solvent e.g., a sterile solution
• the powdered compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, may be packaged in a container, for example, in a vial to which is added the solvent.
• the contents of the vial may be added to the solvent in a separate container.
• the powdered the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26
• a sachet such as a foil package
• the powdered compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26
• a pharmaceutical composition comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, e.g., Composition I, e.g., composition 1.1-1.52, is prepared by admixing the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, with a pharmaceutically acceptable excipient.
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is crystalline.
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1- 2.26, is amorphous.
• the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26 is lyophilized.
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and the pharmaceutically acceptable excipient, e.g., Composition I, e.g., composition 1.1-1.57, is lyophilized.
• a pharmaceutical composition comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, e.g., Composition I, e.g., composition 1.1-1.57, is prepared by admixing the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, with a sterile solution, e.g., sterile water for injection or a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection), to form a pharmaceutically acceptable liquid.
• a sterile solution e.g., sterile water for injection or a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection
• the compound of Formula I e.g., the compound of 1.1- 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is admixed with the sterile solution immediately or shortly before administration.
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is admixed with a buffering agent, e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ), prior to admixture with the sterile solution, e.g., sterile water for injection or a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection).
• a buffering agent e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 )
• the sterile solution e.g., sterile water for injection or a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection).
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is admixed with a buffering agent, e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ), and/or a bulking agent, e.g., dextran (e.g., dextran 40), prior to admixture with the sterile solution, e.g., sterile water for injection or a sterile solution comprising sodium chloride (e.g., 0.9%> sodium chloride injection).
• a buffering agent e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 )
• a bulking agent e.g., dextran (e.g., dextran 40)
• the sterile solution e.g., sterile water for injection or a
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, admixed with the buffering agent and/or the bulking agent is lyophilized.
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is admixed with a sterile solution comprising a buffering agent, e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ).
• a buffering agent e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ).
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is admixed with a sterile solution comprising a buffering agent, e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ) and/or a bulking agent.
• a buffering agent e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ) and/or a bulking agent.
• the admixture of the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and the sterile solution is agitated, e.g., any mode of agitation that results in a clear liquid, e.g., mechanical agitation, sonication, conventional mixing, conventional stirring and the combinations thereof.
• the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, admixed with the sterile solution is lyophilized.
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, admixed with the sterile solution is crystalline.
• the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, admixed with the sterile solution is amorphous.
• Composition I e.g., composition 1.1-1.57
• Composition I is prepared by admixing the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, with a solvent, e.g., a sterile water for injection or a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection).
• a solvent e.g., a sterile water for injection or a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection).
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is admixed with a buffering agent, e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ), and/or a bulking agent, e.g., dextran (e.g., dextran 40), prior to admixture with the solvent.
• a buffering agent e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 )
• a bulking agent e.g., dextran (e.g., dextran 40)
• the solvent comprises a buffering agent, e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ) and/or a bulking agent, e.g., dextran (e.g., dextran 40).
• a buffering agent e.g., sodium citrate and/or sodium phosphate (e.g., Na 2 HP0 4 ) and/or a bulking agent, e.g., dextran (e.g., dextran 40).
• the admixture of the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and the solvent is agitated after admixture, e.g., by any mode of agitation that results in a clear liquid, e.g., mechanical agitation, sonication, conventional mixing, conventional stirring and the combinations thereof.
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is lyophilized.
• the admixture of the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and the buffering agent and/or bulking agent is lyophilized.
• the compound of Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is admixed with the solvent, e.g., the sterile solution, immediately or shortly before administration.
• the solvent e.g., the sterile solution
• compositions disclosed herein e.g., Composition I, e.g., composition 1.1- 1.57, may be contained in a sterilized vessel such as syringes, vials or ampoules of various sizes and capacities.
• kit comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26.
• Kit I As follows:
• Kit I wherein the kit comprises 0.1 or 0.25 mg to 2.0 g of the compound of
• Formula I e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, e.g., from about 0.1 or 0.25 mg to 75 or 600 mg, e.g., from about 0.1 or 0.25 or 1 or 2 or 5 or 10 or 15 or 20 mg to 50, 75, 100, 125, 150, 200, 300, 400, 500, or 600 mg, or 1, 1.5, or 2.0 g, e.g., from about 5 to 50, 75, 100, 125, 150, 200, 300, 400, 500, or 600 mg, or 1 g, 1.5 g, or 2 g, e.g., from about 5 to 500 mg, e.g., from about 5 to 300 mg, e.g., from about 5 to 200 mg, e.g., from about 25 to 500 mg, e.g., from about 25 to 300 mg, e.g., from about 25 to 200 mg, e.g.,
• Kit I or 1.1 wherein the kit comprises 2- ⁇ [3,5- bis(trifluoromethyl)phenyl]carbamoyl ⁇ -4-chlorophenyl dihydrogen phosphate in an amount sufficient to provide a dose of 0.01 or 0.1 or 0.5 mg/kg to 1 or 5 or 10 or 15 mg/kg of N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide, e.g., a dose of about 0.05 to 1 or 5 mg/kg, e.g., a dose of about 0.05 to 0.1, 0.2, 0.3, 0.4, 0.5, 1, 5, 10 or 20 mg/kg, e.g., a dose of about 0.5 to 1, 2, 3, 4, 5 or 10 or 20 mg/kg, e.g, a dose of about 1 to 2, 3, 4, 5, 10, 20 or 50 mg/kg.
• a dose of about 0.05 to 1 or 5 mg/kg e.g., a dose of about 0.05 to 0.1
• Kit I 1.1 , or 1.2 wherein the kit comprises one or more pharmaceutically acceptable excipients.
• Kit 1.3 wherein the one or more pharmaceutically acceptable excipients are selected from the group consisting of buffering agents, bulking agents, solubilizing agents, collapse temperature modifiers and.
• Kit 1.3 or 1 A wherein the kit comprises one or more buffering agents which may control pH, e.g., one or more of sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4 ), potassium phosphate (e.g., KH 2 P0 4 and/or K 2 HP0 4 ), tris(hydroxymethyl)aminomethane (also known as tris base), tris(hydroxymethyl)aminomethane acetate (also known as tris acetate), zinc chloride, meglumine, sodium acetate, potassium acetate, sodium hydroxide, and arginine, e.g., one or more of sodium citrate, Na 2 HP0 4 ,
• buffering agents which may control pH, e.g., one or more of sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4 ), potassium phosphate (e.g., KH 2 P0
• tris(hydroxymethyl)aminomethane and tris(hydroxymethyl)aminomethane acetate, e.g., Na 2 HP0 4 , e.g., tris(hydroxymethyl)aminomethane, e.g.,
• Kit 1.5 wherein the kit comprises 1 or 5 mg to 200 mg or 500 mg of one or more buffering agents, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
• buffering agents e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
• Kit 1.3-1.7 wherein the kit comprises sodium citrate.
• Kit 1.8 wherein the kit comprises 1 or 5 mg to 200 or 500 mg sodium citrate, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium citrate.
• Kit 1.3-1.9 wherein the kit comprises sodium phosphate, e.g., Na 2 HP0 4 .
• Kit 1.3-1.10 wherein the kit comprises Na 2 HP0 4 .
• Kit 1.12 wherein the kit comprises 1 or 5 mg to 200 or 500 mg Na 2 HP0 4 , e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg Na 2 HP0 4 .
• Kit 1.3-1.13 wherein the kit comprises one or more bulking agents which may provide an adequate structure to the lyophilized cake, e.g., one or more of mannitol, lactose, sucrose, trehalose, sorbitol, glucose, raffmose, arginine, glycine, histidine, dextran (e.g., dextran 40), polyvinylpyrrolidone, polyethylene glycol, and polypropylene glycol, e.g., one or more of mannitol, glucose, sucrose, lactose, trehalose, and dextran (e.g., dextran 40).
• the kit comprises one or more bulking agents which may provide an adequate structure to the lyophilized cake, e.g., one or more of mannitol, lactose, sucrose, trehalose, sorbitol, glucose, raffmose, arginine, glycine, histidine, de
• Kit 1.14 the kit comprises 5 or 10 or 50 mg to 2 or 5 g of one or more bulking agents, e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g of one or more bulking agents.
• Kit 1.3-1.15 wherein the kit comprises dextran (e.g., dextran 40).
• dextran e.g., dextran 40
• Kit 1.16 wherein the kit comprises 5 or 10 or 50 mg to 2 or 5 g dextran (e.g., dextran 40), e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g dextran (e.g., dextran 40).
• dextran e.g., dextran 40
• the kit comprises 5 or 10 or 50 mg to 2 or 5 g dextran (e.g., dextran 40), e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g dextran (e.g., dextran 40).
• Kit 1.3-1.17 wherein the composition comprises one or more solubilizing agents, e.g., ethylenediamine tetraacetic acid (EDTA) or a slat thereo (e.g., calcium disodium EDTA, disodium EDTA, sodium EDTA), alpha cyclodextrin, hydroxypropyl- -cyclodextrin, polysorbate 80, tert-butanol, isopropanol, dichloromethane, ethanol, acetone, and glycerol; one or more collapse
• solubilizing agents e.g., ethylenediamine tetraacetic acid (EDTA) or a slat thereo (e.g., calcium disodium EDTA, disodium EDTA, sodium EDTA), alpha cyclodextrin, hydroxypropyl- -cyclodextrin, polysorbate 80, tert-butanol, isopropan
• temperature modifiers which may shift the overall collapse temperature higher, e.g., one or more of dextran, Ficoll ® , gelatin, and hydroxyethyl starch; one or more tonicity modifiers, e.g., one or more of sodium chloride, potassium chloride, sucrose, mannitol, glucose, and lactose; and one or more antimicrobial agents, e.g., one or more of benzyl alcohol, phenol, 2-phenoxyethanol, m-cresol, parabens (e.g., methyl paraben, ethyl paraben, propyl paraben), benzalkonium chloride, benzethonium chloride, myristyl gamma-picolinium salt (e.g., myristyl gamma- picolinium chloride), and organomercury compounds and salts (e.g., phenyl mercuric acetate, phenyl mercuric borate,
• Kit 1.3-1.18 wherein the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and the one pharmaceutically acceptable excipients are in the same container or in one or more different containers.
• Kit 1.19 wherein the kit comprises one or more buffering agents, e.g, sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4 ), potassium phosphate (e.g., KH 2 P0 4 and/or K 2 HP0 4 ),
• buffering agents e.g, sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4 ), potassium phosphate (e.g., KH 2 P0 4 and/or K 2 HP0 4 ),
• tris(hydroxymethyl)aminomethane acetate also known as tris acetate
• zinc chloride meglumine
• sodium acetate potassium acetate
• sodium hydroxide sodium hydroxide
• arginine e.g., one or more of sodium citrate, Na 2 HP0 4 ,
• tris(hydroxymethyl)aminomethane and tris acetate, e.g., Na 2 HP0 4 , e.g., tris(hydroxymethyl)aminomethane, e.g., tris(hydroxymethyl)aminomethane acetate, wherein the one or more buffering agents are in the same container as the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, or in one or more different containers.
• Kit 1.20 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and one or more of sodium citrate and sodium phosphate (e.g., Na 2 HP0 4 ) are in the same container or in one or more different containers.
• the compound of Formula I e.g., the compound of 1.1 - 1.52
• the compound of Formula II e.g., the compound of 2.1-2.26
• sodium citrate and sodium phosphate e.g., Na 2 HP0 4
• Kit 1.20 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and sodium citrate are in the same container or in different containers.
• Kit 1.20 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and sodium phosphate (e.g., Na 2 HP0 4 ) are in the same container or in different containers.
• the compound of Formula I e.g., the compound of 1.1 - 1.52
• the compound of Formula II e.g., the compound of 2.1-2.26
• sodium phosphate e.g., Na 2 HP0 4
• Kit 1.19-1.23 wherein the kit comprises one or more bulking agents, e.g., one or more of mannitol, lactose, sucrose, trehalose, sorbitol, glucose, raffmose, arginine, glycine, histidine, dextran (e.g., dextran 40), polyvinylpyrrolidone, polyethylene glycol, and polypropylene glycol, e.g., one or more of mannitol, glucose, sucrose, lactose, trehalose, and dextran (e.g., dextran 40), wherein the one or more bulking agents are in the same container as the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, or any other component of the kit, or in one or more different containers, e.g., in any combination in any number of different containers.
• Kit 1.24 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and dextran (e.g., dextran 40) are in the same container or in different containers.
• the compound of Formula I e.g., the compound of 1.1 - 1.52
• the compound of Formula II e.g., the compound of 2.1-2.26
• dextran e.g., dextran 40
• Kit 1.19-1.25 wherein the kit comprises one or more solubilizing agents, e.g., ethylenediamine tetraacetic acid (EDTA) or a salt thereof (e.g., calcium disodium EDTA, disodium EDTA, sodium EDTA), alpha cyclodextrin, hydroxypropyl- ⁇ - cyclodextrin, polysorbate 80, tert-butanol, isopropanol, dichloromethane, ethanol, acetone, and glycerol; one or more collapse temperature modifiers, e.g., one or more of dextran, Ficoll ® , gelatin, and hydroxyethyl starch; one or more tonicity modifiers, e.g., one or more of sodium chloride, potassium chloride, sucrose, mannitol, glucose, and lactose; and one or more antimicrobial agents, e.g., one or more of benzyl alcohol, phenol,
• Kit I or 1.1 - 1.26 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is crystalline.
• Kit I or 1.1 - 1.26 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is amorphous.
• Kit I or 1.1 - 1.28 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is lyophilized, e.g., by freezing, primary drying, and secondary drying.
• Kit 1.2-1.29 wherein the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and the one or more pharmaceutically acceptable excipients are lyophilized.
• Kit I or 1.1 - 1.30 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is suitable for constitution, or reconstitution if lyophilized, with a solvent into a pharmaceutically acceptable liquid (e.g., a solution or suspension, e.g., a
• Kit I or 1.1-1.31 wherein the kit comprises a solvent, e.g., a sterile solution, e.g., sterile water for injection, a sterile solution comprising dextrose (e.g., dextrose injection 5%), a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection), a sterile solution comprising benzyl alcohol (e.g., a solvent, e.g., a sterile solution, e.g., sterile water for injection, a sterile solution comprising dextrose (e.g., dextrose injection 5%), a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection), a sterile solution comprising benzyl alcohol (e.g.,
• a solvent e.g., a sterile solution, e.g., sterile water for injection
• Kit I or 1.1-1.32 wherein the kit comprises 0.5 to 500 mL solvent, e.g., from about 1 to 2 or 500 mL, e.g., from about 1 or 2 to 5, 10, 25, 50, 75, 100, 150, 200, 300 or 500 mL, e.g., from about 1 or 2 to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• 0.5 to 500 mL solvent e.g., from about 1 to 2 or 500 mL, e.g., from about 1 or 2 to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 1 or 2 to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• Kit I or 1.1-1.33 wherein the kit comprises 0.5 to 500 mL sterile solution, e.g., sterile water for injection, a sterile solution comprising dextrose (e.g., dextrose injection 5%), a sterile solution comprising sodium chloride (e.g., 0.9% sodium chloride injection), a sterile solution comprising benzyl alcohol (e.g.,
• bacteriostatic water for injection with benzyl alcohol or bacteriostatic sodium chloride for injection with benzyl alcohol), or Lactated Ringer's e.g., from about 1 or 2 mL to 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, 150, 200, 300 or 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• Kit I or 1.1 - 1.34 wherein the kit comprises sterile water for injection or a sterile solution comprising sodium chloride (e.g., 0.9%> sodium chloride injection).
• Kit 1.35 wherein the kit comprises 0.5 to 500 mL sterile water for injection, e.g., from about 1 or 2 mL to 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, 150, 200, 300 or 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• Kit I or 1.1 - 1.36 wherein the kit comprises sterile solution comprising sodium chloride (e.g., 0.9%> sodium chloride injection).
• Kit 1.37 wherein the kit comprises 0.5 to 500 mL of a sterile solution comprising sodium chloride (e.g., 0.9%> sodium chloride injection), e.g., from about 1 or 2 mL to 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, 150, 200, 300 or 500 mL, e.g., from about 1 or 2 mL to 5, 10, 25, 50, 75, 100, or 200 mL, e.g., from about 5 to 10, 25, 50, or 100 mL.
• sodium chloride e.g. 0.9%> sodium chloride injection
• Kit 1.31-1.38 wherein the solvent, e.g., the sterile solution, comprises a buffering agent, e.g., one or more of sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4 ), potassium phosphate (e.g., KH 2 P0 4 and/or K 2 HP0 4 ), tris(hydroxymethyl)aminomethane (also known as tris
• a buffering agent e.g., one or more of sodium citrate, potassium citrate, sodium phosphate (e.g., NaH 2 P0 4 and/or Na 2 HP0 4 ), potassium phosphate (e.g., KH 2 P0 4 and/or K 2 HP0 4 ), tris(hydroxymethyl)aminomethane (also known as tris
• tris(hydroxymethyl)aminomethane acetate also known as tris acetate
• zinc chloride meglumine
• sodium acetate potassium acetate
• sodium hydroxide sodium hydroxide
• arginine e.g., one or more of sodium citrate, Na 2 HP0 4 ,
• tris(hydroxymethyl)aminomethane and tris(hydroxymethyl)aminomethane acetate, e.g., Na 2 HP0 4 , e.g., tris(hydroxymethyl)aminomethane, e.g.,
• Kit 1.39 wherein the solvent, e.g., the sterile solution, comprises 1 or 5 mg to 200 or 500 mg of one or more buffering agents, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
• the solvent e.g., the sterile solution
• the buffering agents e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg.
• Kit 1.39-1.41 wherein the solvent, e.g. the sterile solution, comprises sodium citrate.
• Kit 1.42 wherein the solvent, e.g., the sterile solution, comprises 1 or 5 mg to 200 or 500 mg sodium citrate, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium citrate.
• the solvent e.g., the sterile solution
• the solvent comprises 1 or 5 mg to 200 or 500 mg sodium citrate, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium citrate.
• Kit 1.39-1.43 wherein the solvent, e.g., the sterile solution, comprises sodium phosphate, e.g., Na 2 HP0 4 .
• Kit 1.44 wherein the solvent, e.g., the sterile solution, comprises 1 or 5 mg to 200 or 500 mg sodium phosphate, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium phosphate, e.g., Na 2 HP0 4 .
• the solvent e.g., the sterile solution
• the solvent comprises 1 or 5 mg to 200 or 500 mg sodium phosphate, e.g., from about 1 or 5 or 10 mg to 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg sodium phosphate, e.g., Na 2 HP0 4 .
• Kit 1.32-1.45 wherein the solvent, e.g., the sterile solution, comprises one or more bulking agents, e.g., one or more of maltose, mannose, ribose, cyclodextrin, mannitol, lactose, sucrose, trehalose, sorbitol, glucose, raffmose, arginine, glycine, histidine, dextran (e.g., dextran 40), polyvinylpyrrolidone, polyethylene glycol, and polypropylene glycol, e.g., one or more of mannitol, glucose, sucrose, lactose, trehalose, and dextran (e.g., dextran 40).
• the solvent e.g., the sterile solution
• the solvent comprises one or more bulking agents, e.g., one or more of maltose, mannose, ribose, cyclodextrin, mann
• Kit 1.32-1.46 wherein the solvent, e.g., the sterile solution, comprises 5 or 10 or 50 mg to 2 or 5 g of one or more bulking agents, e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g of one or more bulking agents.
• Kit 1.32-1.47 wherein the solvent, e.g., the sterile solution, comprises dextran (e.g., dextran 40).
• Kit 1.48 wherein the solvent, e.g. the sterile solution, comprises 5 or 10 or 50 mg to 2 or 5 g dextran (e.g., dextran 40), e.g., from about 50 or 100 mg to 200, 300, 500, or 800 mg, or 1, 1.5, 2, 3, 4, or 5 g dextran (e.g., dextran 40).
• dextran e.g., dextran 40
• Kit 1.32- 1.50 wherein the compound of Formula I, e.g., the compound of 1.1 - 1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, is admixed with the solvent to form a solution wherein the pH is between pH 7 and pH 10.5, e.g., between pH 7 and pH 9.5, e.g., between pH 7 and pH 8.
• Kit 1.51 wherein the solution is filtered to remove particles and microbes, e.g., filtered prior to injection.
• Kit 1.51 or 1.52 wherein the solution is administered about 24 hours, 12 hours, 10 hours, 8 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, 15 minutes, 10 minutes, 5 minutes, 3 minutes, 2 minutes or 1 minute or less after admixture.
• Kit I or 1.1 - 1.53 wherein the kit comprises one or more additional therapeutic agents, e.g., one or more additional therapeutic agents for cerebral edema, stroke, traumatic brain injury, glioma (e.g., glioblastoma), meningitis, acute mountain sickness, infection, metabolic disorder, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, lupus cerebritis, optic nerve edema, hyponatremia, fluid retention, ovarian hyperstimulation syndrome, epilepsy, retinal ischemia or other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, neuromyelitis optica
• Kit I or 1.1-1.128 wherein the kit comprises one or more additional therapeutic agents, e.g., one or more additional therapeutic agents for pulmonary edema, fibromyalgia, or multiple sclerosis.
• additional therapeutic agents e.g., one or more additional therapeutic agents for pulmonary edema, fibromyalgia, or multiple sclerosis.
• Kit I or 1.1-1.55 wherein the kit comprises instructions for using the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, to treat or control a disease or condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases, for example, edema of the brain or spinal cord, e.g., cerebral edema, e.g.
• an aquaporin e.g., diseases or conditions of water imbalance and other diseases, for example, edema of the brain or spinal cord, e.g., cerebral edema, e.g.
• cerebral edema consequent to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, hypoxia (including general systemic hypoxia and hypoxia due to cardiac arrest), water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, lupus cerebritis, cardiac arrest, microgravity and/or radiation exposure, or an invasive central nervous system procedure, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation or, e.g., spinal cord edema consequent to spinal cord trauma, e.g., spinal cord compression; or optic nerve edema, e.g., optic nerve edema consequent to microgravity and/or radiation exposure; or retinal edema; or hyponatremia or excessive fluid retention,
• Kit I or 1.1-1.56 wherein the kit comprises instructions for using 2- ⁇ [3,5- bis(trifluoromethyl)phenyl]carbamoyl ⁇ -4-chlorophenyl dihydrogen phosphate to treat or control a disease or condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases, for example, pulmonary edema, fibromyalgia, or multiple sclerosis.
• an aquaporin e.g., diseases or conditions of water imbalance and other diseases, for example, pulmonary edema, fibromyalgia, or multiple sclerosis.
• Kit I or 1.1 -1.57 wherein the kit comprises instructions for administering the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, to a patient in need thereof.
• the kit comprises instructions for administering the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, to a patient in need thereof.
• Kit I or 1.1-1.57 wherein the kit comprises instructions for mixing the compound of Formula I, e.g., the compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, and one or more pharmaceutically acceptable excipients.
• Kit I wherein the kit comprises a pharmaceutical composition comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, e.g., Composition I, e.g., a composition of 1.1-1.57.
• a pharmaceutical composition comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, e.g., Composition I, e.g., a composition of 1.1-1.57.
• Kit 1.60 wherein the kit comprises instructions for using the pharmaceutical composition to treat or control a disease or condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases, for example, edema of the brain or spinal cord, e.g., cerebral edema, e.g.
• an aquaporin e.g., diseases or conditions of water imbalance and other diseases, for example, edema of the brain or spinal cord, e.g., cerebral edema, e.g.
• cerebral edema consequent to head trauma, ischemic stroke, glioma, meningitis, acute mountain sickness, epileptic seizure, infection, metabolic disorder, hypoxia (including general systemic hypoxia and hypoxia due to cardiac arrest), water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt- Jakob disease, lupus cerebritis, cardiac arrest, microgravity and/or radiation exposure, or an invasive central nervous system procedure, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation or, e.g., spinal cord edema consequent to spinal cord trauma, e.g., spinal cord compression; or optic nerve edema, e.g., optic nerve edema consequent to microgravity and/or radiation exposure; or retinal edema; or hyponatremia or excessive fluid retention,
• kit comprises instructions for using the pharmaceutical composition to treat or control a disease or condition mediated by an aquaporin, , e.g., diseases or conditions of water imbalance and other diseases, for example, pulmonary edema, fibromyalgia, or multiple sclerosis.
• an aquaporin e.g., diseases or conditions of water imbalance and other diseases, for example, pulmonary edema, fibromyalgia, or multiple sclerosis.
• Kit 1.60 wherein the kit comprises instructions for administering the
• Kit 1.60 wherein the kit comprises instructions for preparing the pharmaceutical composition.
• Kit I or 1.1 - 1.64 wherein the kit is for use in any of the methods described herein, e.g., for use in Method A, e.g., Method A.1-A.58, for use in Method B, e.g., Method B.1-B.41, e.g., for use in Method C, e.g., C.1-C.8, e.g., for use in Method D, e.g., D.1-D.19, e.g., for use in Method E, e.g., E.1-E.5, e.g., for use in Method F, e.g., F.1-F.5, e.g., for use in Method G, e.g., G.1-G.58.
• Method A e.g., Method A.1-A.58
• Method B e.g., Method B.1-B.41
• Method C e.g., C.1-C.8,
• the kit is prepared by transferring a liquid comprising a compound of Formula I, e.g., a compound of 1.1-1.52, or, e.g., the compound of Formula II, e.g., the compound of 2.1-2.26, to a container, e.g., a vial, in a predetermined volume first and then subjecting the liquid to a lyophilization process.
• a container e.g., a vial
• liquid can be lyophilized in a large volume and then a predetermined amount of the lyophilized preparation can be placed in a container.
• R 30 , R 31 , R 32 , R 33 , and R 34 are independently H, halogen (e.g., CI or Br), Ci_ 4 -alkyl, Ci_ 4 -haloalkyl (e.g., -CF 3 ), or cyano; and
• R 3"5 and R 3 J 6 0 are independently protecting groups, e.g., wherein R 35 and R 36 are independently a protecting group comprising Si, S, N, and/or O, e.g., wherein R 35 and R 36 are independently a protecting group comprising an optionally substitututed cyclic or acyclic ether, an optionally substituted silyl (e.g., -Si(Ci_6-alkyl) 3 , e.g., -Si(Ci_ 4 -alkyl) 3 , e.g., -Si(CH 3 ) 3 ), an optionally substituted silyl ether, an optionally substituted ester, an optionally substituted ketone, or an optionally substituted thioether, e.g., wherein R 35 and R 36 are independently -CH 2 OR, -CH 2 SR,
• each R is independently H, Ci_ 6 -alkyl (e.g., Ci_ 4 -alkyl), -CH 2 Si(R") 3 , -CH 2 -Aryl (e.g., phenyl), -Ci_ 6 - alkenyl, -CH 2 OSi(R") 3 , alkoxyalkyl, or -CH 2 CH 2 Si(R") 3 and each R" is independently Ci_ 6 -alkyl
• Ci_ 4 -alkyl or aryl optionally substituted with alkoxy (e.g., -Ci_ 6 -alkoxy, e.g., -Ci_ 4 -alkoxy), halogen, cyano, or aryl (e.g., phenyl), wherein each R is optionally substituted with alkyl, alkoxyalkyl, or aryl, e.g., -(CH 2 CH 2 ) n -Si(R 37 ) 3 ), wherein each R 37 is independently Ci_ 6 -alkyl, e.g., Ci_ 4 -alkyl and n is 0 or 1,
• R 35 and R 36 are not both -CH 2 -C 6 H5.
• R 30 , R 31 , R 32 , R 33 , and R 3 J 4 are independently selected from H, halogen (e.g., CI or Br), Ci_ 4 -haloalkyl (e.g., -CF 3 ), and cyano.
• R 30 , R 31 , R 32 , R 33 , and R 3 J 4 are independently selected from H, halogen (e.g., CI or Br), and Ci_ 4 -haloalkyl (e.g., -CF 3 ).
• R 30 , R 32 , and R 34 are independently selected from halogen (e.g., CI or Br) and Ci_ 4 -haloalkyl (e.g., -CF 3 ) and R 31 and R 33 are H.
• R 30 , R 32 , and R 3 J 4 are independently halogen (e.g., CI or Br) and R 31 and R 33 are H.
• Formula III or 3.1-3.4 wherein R 30 , R 32 , and R 34 are CI and R 31 and R 33 are H.
• Formula III or 3.1-3.3 wherein R , R , and R are independently Ci_4-haloalkyl (e.g., -CF 3 ) and R 31 and R 33 are H.
• R , R , and R J are independently F, CI, Br, or -CF 3 and R 31 and R 33 are H.
• R is halogen (e.g., CI or Br), R and R are H, and R 32 and R 34 are independently Ci_4-haloalkyl (e.g., -CF 3 ).
• R 30 , R 31 , R 32 , R 33 , and R 34 are independently H, halogen (e.g., CI or Br), or cyano.
• R and R are independently halogen (e.g., CI or Br), R and R 34 are H, and R 33 is cyano.
• R 35 and R 36 are independently selected from a protecting group comprising Si.
• R 35 and R 36 are independently selected from -(CH 2 CH 2 ) n -Si(R 37 ) 3 , wherein each R 37 is independently Ci_ 6 -alkyl, e.g., Ci_ 4 - alkyl, e.g., -CH 3 , and n is 0 or 1 , e.g., 0, e.g., 1.
• R 35 and R 36 are -CH 2 -CH 2 -Si(CH 3 ) 3 .
• R 40 and R 41 are independently protecting groups, e.g., wherein R 40 and R 41 are independently a protecting group comprising Si, S, N, and/or O, e.g., wherein R 40 and R 41 are independently a protecting group comprising an optionally substitututed cyclic or acyclic ether, an optionally substituted silyl (e.g., -Si(Ci_6-alkyl) 3 , e.g., -Si(Ci_4-alkyl) 3 , e.g., -Si(CH 3 ) 3 ), an optionally substituted silyl ether, an optionally substituted ester, an optionally substituted ketone, or an optionally substituted thioether, e.g., wherein R 40 and R 41 are independently -CH 2 OR, -CH 2 SR,
• each R is independently H, Ci_ 6 -alkyl (e.g., Ci_ 4 -alkyl), -CH 2 Si(R") 3 , -CH 2 -Aryl (e.g., phenyl), -Ci_ 6 - alkenyl, -CH 2 OSi(R") 3 , alkoxyalkyl, or -CH 2 CH 2 Si(R") 3 and each R" is independently Ci_ 6 -alkyl
• Ci_ 4 -alkyl or aryl optionally substituted with alkoxy (e.g., -Ci_ 6 -alkoxy, e.g., -Ci_ 4 -alkoxy), halogen, cyano, or aryl (e.g., phenyl), wherein each R is optionally substituted with alkyl, alkoxyalkyl, or aryl, e.g., -(CH 2 CH 2 ) n -Si(R 37 ) 3 ), wherein each R 37 is independently Ci_ 6 -alkyl, e.g., Ci_ 4 -alkyl and n is 0 or 1,
• R 41 and R 341 are not both -CH 2 -C 6 Hs.
• each R 37 is independently Ci_ 4 -alkyl, e.g., -CH 3 , and n is 0 or 1.
• compounds of 2.1-2.26 include their polymorphs, hydrates, solvates and complexes.
• Some individual compounds within the scope of this disclosure may contain double bonds. Representations of double bonds herein are meant to include both the E and the Z isomer of the double bond. In addition, some compounds within the scope of this disclosure may contain one or more asymmetric centers. This disclosure includes the use of any of the optically pure stereoisomers as well as any combination of stereoisomers.
• Stable isotopes are nonradioactive isotopes which contain one additional neutron compared to the abundant nuclides of the same species (i.e., element). It is expected that the activity of compounds comprising such isotopes would be retained, and such compound would also have utility for measuring pharmacokinetics of the non-isotopic analogs.
• the hydrogen atom at a certain position on a compound of Formula I may be replaced with deuterium (a stable isotope which is nonradioactive).
• a stable isotope which is nonradioactive examples include, but not limited to, deuterium, 13 C, 15 N, 18 0.
• unstable isotopes which are radioactive isotopes which contain additional neutrons compared to the abundant nuclides of the same species (i.e., element), e.g., 123 I, 131 I, 125 I, U C, 18 F, may replace the corresponding abundant species of I, C, and F.
• a useful isotope of a compound of Formula I e.g., a compound of 1.1-1.52, or, e.g., a compound of Formula II, e.g., a compound of 2.1-2.26, or a compound of Formula III, e.g., a compound of formula 3.1-3.21, is the U C isotope.
• radio isotopes may be useful for radio-imaging and/or pharmacokinetic studies of compounds of Formula I, e.g., compounds of 1.1-1.52, or, e.g., compounds of Formula II, e.g., compounds of 2.1-2.26.
• Compounds of Formula I e.g., compounds of formula 1.1-1.52, or, e.g., compounds of Formula II, e.g., compounds of formula 2.1-2.26, and compounds of Formula III, e.g., 3.1-3.21, may be made using the methods as described and exemplified herein and by methods similar thereto and by methods known in the chemical art. Such methods include, but not limited to, those described below. If not commercially available, starting materials for these processes may be made by procedures which are selected from the chemical art using techniques which are similar or analogous to the synthesis of known compounds.
• novel processes for the synthesis compounds of Formula I e.g., compounds of formula 1.1-1.52, or, e.g., compounds of Formula II, e.g., compounds of formula 2.1-2.26.
• Novel intermediates of Formula III e.g., compounds of formula 3.1-3.21, may be used in the synthesis of compounds of Formula I, e.g., compounds of formula 1.1-1.52 and in the synthesis of compounds of Formula II, e.g., compounds of formula 2.1-2.26.
• U.S. Patent No. 7,626,042 describes that palladium hydroxide on carbon was added to Compound No. 50 in ethyl acetate and the mixture was stirred at room temperature for 1 hour under hydrogen atmosphere.
• R 1 , R 2 , R 3 , R 4 , R 5 , and Q are as defined for Formula I.
• R 1 , R 2 , R 3 , R 4 , and R 5 are independently H, halogen (e.g., CI or Br), Ci_4-haloalkyl (e.g., -CF 3 ), or cyano.
• R 1 , R 2 , R 3 , R 4 , and R 5 are independently H, halogen (e.g., CI or Br), or Ci_4-haloalkyl (e.g., -CF 3 ).
• R 1 , R 3 , and R 5 are independently halogen (e.g., CI or Br) or Ci_ 4 -haloalkyl (e.g., -CF 3 ) and R 2 and R 4 are H.
• R 1 and R 2 are independently halogen (e.g., CI or Br), R 3 and R 5 are H, and R 4 is cyano.
• Q comprises N, e.g., Q is HOR 8 NH 2 , (HOR 8 ) 2 NH, or (HOR 8 ) 3 N.
• Q comprises sodium (e.g., NaOH, NaHC0 3 , Na 2 C0 3 , NaOMe, NaOEt, or NaH).
• Q comprises potassium (e.g., KOH, KHC0 3 , K 2 C0 3 , KOMe, KOEt, or KH).
• R 1 is halogen (e.g., CI or Br)
• R 2 and R 4 are H
• R 3 and R 5 are independently Ci_4-haloalkyl (e.g., -CF 3 ).
• Q comprises sodium (e.g., NaOH, NaHC0 3 , Na 2 C0 3 , NaOMe, NaOEt, NaH).
• Q comprises sodium (e.g., NaOH, NaHC0 3 , Na 2 C0 3 , NaOMe, NaOEt, NaH).
• Q comprises potassium (e.g., KOH, KHC0 3 , K 2 C0 3 , KOMe, KOEt, KH).
• Process I or 1.1-1.51 wherein the reaction occurs in a solvent selected from one or more of H 2 0 and an alcohol (e.g., methanol, ethanol, isopropanol).
• a solvent selected from one or more of H 2 0 and an alcohol (e.g., methanol, ethanol, isopropanol).
• Process I or 1.1-1.55 wherein the reaction is stirred for about 2 hours.
• Process I or 1.1-1.56 wherein the compound of Formula IV is mono-deprotonated.
• Process I or 1.1-1.56 wherein the compound of Formula IV is di-deprotonated Process I or 1.1-1.58 further comprising deprotecting a compound of Formula III
• R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , and R 36 are as defined above, e.g., a compound of Formula III, e.g., a compound of formula 3.1-3.21, to form a compound of Formula IV.
• R 35 and R 36 are as defined above, e.g., a compound of Formula III, e.g., a compound of formula 3.1-3.21.
• Process 1.59-1.66 wherein the deprotection reaction is stirred for about 2 hours.
• Process I or 1.1 - 1.67 further comprising reacting a compound of Formula V
• Formula VI to form a compound of Formula III, wherein R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , and R 36 are as defined above for the compound of Formula III, e.g., the compound of formula 3.1-3.21, e.g., wherein the compound of Formula VI is a compound of Formula XX, e.g., 20.1-20.5.
• Process 1.68 wherein the compound of Formula V is reacted with a compound of Formula XX, e.g., 20.1-20.5.
• Process 1.68-1.74 wherein the reaction occurs in the presence of a catalyst.
• Process 1.75 wherein the catalyst comprises nitrogen.
• Process 1.76 wherein the catalyst is 4-dimethylaminopyridine (also known as DMAP), l,8-diazabicyclo[5.4.0]undec-7-ene (also known as DBU), or 1,5- diazabicyclo[4.3.0]non-5-ene (also known as DBN).
• DMAP 4-dimethylaminopyridine
• DBU l,8-diazabicyclo[5.4.0]undec-7-ene
• DBN 1,5- diazabicyclo[4.3.0]non-5-ene
• Process 1.68-1.78 wherein the reaction is allowed to warm from about 0°C to room temperature.
• Process I or 1.1-1.80 further comprising reacting a compound of Formula VII
• R , R , R , and IT * are as defined above for the compound of Formula III, e.g., 3.1-3.21.
• Process 1.81 or 1.82 further comprising first converting the compound of Formula VII to a compound of Formula IX
• R 30 is as defined above.
• Process 1.84 wherein Formula IX is formed by reaction with PC1 3 , PCI 5 , or SOCl 2 . 6
• Process 1.82-1.85 wherein the reaction occurs in a nonpolar solvent.
• Formula I Formula IV Formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , and R 36 are as defined above.
• R 6 and R 7 are as defined above.
• R 6 and R 7 are as defined above.
• Process I or 1.1 - 1.92 further comprising isolating the compound of Formula I, e.g., the compound of formula 1.1-1.52.
• Hunig's base N,N-diisopropylethylamine
• Step 2 2-((3,5-bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl bis(2- (trimethylsilyl)ethyl) phosphate
• N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide (4.0 g, 0.01 mol, 1 eq) is dissolved in CH 3 CN (104 mL) then DMAP (0.08 g, 0.001 mol, 0.06 eq), Hunig's base (7.36 mL, 0.021 mol, 2 eq) and CCI4 (8.02 g, 0.052 mol, 5 eq) are added in this order.
• Step 3 2-((3,5-bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate
• 2-((3,5-bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl hydrogen phosphate mono ethanolamine salt is made as follows: 1 g of 2-((3,5- bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate is dissolved in isopropanol and 1 eq ethanol amine is added. Evaporation gave 2-((3,5- bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl hydrogen phosphate mono ethanolamine salt.
• Structure activity relationships are determined by assaying analogues of selected hits to guide chemistry for the preparation of new molecules to be tested for improved potency.
• a quantitative kinetic assay - the Aquaporin-Mediated Cell Volume Change Assa - in a 96-well multiplate reader. It detects changes in light scattering by a monolayer of CHO cells expressing the desired AQP as they shrink when exposed to hypertonic solution (300 mOsm ⁇ 530 mOsm).
• Figure 1 depicts the aquaporin-mediated cell volume change assay with AQP4 expressing cells ( Figure 1 A) and AQP2 expressing cells ( Figure IB).
• the cells expressing aquaporins shrink more rapidly than control cells, due to enhanced water flow, which shrinkage can be inhibited by a compound that inhibits the aquaporin.
• Figure 1 A when the AQP4b cells treated with DMSO are exposed to hypertonic shock, the cells show rapid shrinking, giving a rise in light scattering (increasing relative change in absorbance, Abs/Abso) followed by a decay as cells detach from the plate.
• the CHO-AQP4b cell line shows a 4.5-fold increase in the rate of shrinking compared to CHO- CD81 control cells (fitted to a double exponential model).
• CHO-AQP4b cells treated with the Compound 3 analogue at 10 ⁇ squares
• Figure IB depicts an experiment comparing CHO-AQP2 treated with DMSO or with Compound 3 at 10 ⁇ .
• Aquaporin-2 has a lower intrinsic water permeability than AQP4 as observed here.
• CHO-AQP2 cell lines treated with DMSO (Figure IB, triangles) show a 1.7-fold increase in the rate of shrinking compared to CHO-CD81 control cells (diamonds) also treated with DMSO (fitted to a double exponential model) ( Figure IB).
• CHO-AQP2 cells treated with Compound 3 at 10 ⁇ squares show a slower rate of shrinking (81% inhibition), when comparing the relative change in Abs (Abs/Abso) ( Figure IB).
• Compound 3 is capable of significantly inhibiting AQP2 and AQP4 activity, e.g. by greater than 50%, at concentrations of 10 ⁇ .
• AQP4 we perform in vitro binding studies using purified AQP4b and Compound 4 radiolabeled with 3 H.
• a Hummel-Dryer style assay a gel filtration column is equilibratrated with buffer containing detergent, to maintain solubility of AQP4b, and 1 ⁇ [ 3 H]-Compound 4.
• AQP4b is diluted to 250 ⁇ in this column buffer and incubated at RT for 30 min. The sample is then applied to the column, fractions collected and the presence of [ 3 H]-Compound 4 detected by liquid scintillation counting.
• Figure 3 shows the elution profile of [ 3 H]-Compound 4 from the gel filtration column with the elution positions of tetrameric and monomeric AQP4b indicated.
• the rise in [ 3 H]-Compound 4 from a baseline value of 1 ⁇ represents binding to each of these proteins.
• this assay reveals the presence of a small, albeit vanishing, amount of monomer.
• the relative affinities for Compound 4 are -100 ⁇ and less than 1 ⁇ for tetramer and monomer, respectively.
• This assay shows relatively weak binding of Compound 4 to solubilized AQP4b; nevertheless, it clearly demonstrates that this phenylbenzamide directly interacts with AQP4b.
• EXAMPLE 13 Pharmacological Proof-of-Concept
• mice The ability of mice to survive H 2 0 toxicity is determined in three experiments using 10-12 mice each (16-19 weak old male/female). Deionized water is prepared for injection with either 0.39 mg/kg phenylbenzamide (placebo) or 0.76 mg/kg with test compound.
• MRI Magnetic resonance Imaging
• Each scan contains twenty-five 0.7 mm contiguous imaging slices of which 14-15 slices contain a portion of the brain.
• the cross sectional area of the brain in each imaging slice is measured by manual region-of-interest selection using ImageJ. Brain volumes are then calculated for each scan by summing the individual cross sectional brain areas and multiplying by the slice thickness (0.7 mm).
• Calcein fluorescence end-point assay Cells are seeded 24 hr before assay to reach 100% confluence. Culture medium is replaced with H 2 0 for 5:30 min (osmotic shock). Osmolality is then normalized with the addition of 2x PBS plus 2 ⁇ calcein-AM. Cells are then incubated at 37°C for an additional 30 min and fluorescence measured on a plate-reader. Rows 1- 22 are seeded with CHO-AQP4 cells, and rows 23-24, with CHO-CD81 cells (384 well plate). Note, all plate edges are discarded.
• Relative Fluorescence Intensity is calculated as the fluorescence intensity (FI) of each well divided by the mean FI of AQP4 cells treated with DMSO (control). Criteria for a successful assay: coefficients of variation (CVs) ⁇ 15%, and Z- factors > 0.5. Statistical analysis shows that 5.5 min of osmotic shock provides the optimal signal-to-noise ratio.
• the signal for the CD81 cells is ca. 5x higher than the signal for the APQ4 cells, because by 5.5 mins, most of the AQP4 cells have burst, while most of the CD81 cells remain intact. Inhibition of AQP4 would therefore be expected to provide a higher signal, more like the CD81 cells.
• This assay is applied in a pilot screen of the MicroSource GenPlus 960 and the
• Hits from the HTS are validated using the same assay using a different plating arrangement.
• Figure 7 we show this validation assay used to examine Compound 3.
• CHO cells expressing CD81 are seeded in lanes 2-3 as a control, and CHO cells expressing AQP4, in lanes 4-23.
• Cells are treated with 0.1% DMSO in 10% FBS, DMEM (even numbered columns) or 10 ⁇ Compound 1 (odd number columns) in 0.1 % DMSO, 10%> FBS, DMEM for 30 minutes.
• the cells are shocked with H 2 0 for 5:30 minutes, then osmolality returned to 300 mOSM in the presence of 1 ⁇ calcein-AM, as described above.
• the cells are incubated at 37°C for 30 minutes and the relative fluorescence measured (ex 495/em 535 nM) on a fluorescence multiplate reader.
• ICP is monitored using a Samba 420 Sensor, pressure transducer, with a Samba
• This ICP monitoring system consists of a 0.42 mm silicon sensor element mounted on an optical fiber.
• a 20-gauge syringe needle is implanted through the cisterna magna to a depth of ⁇ 1 cm. The needle then acts as a guide for insertion of the Samba Sensor and the site of implantation and the open end of the needle are sealed with 100% silicone sealant.
• a baseline ICP reading is established followed by a water bolus IP injection (20% weight of animal) with or without Compound 1. ICP is monitored until the animal expires from the water load.
• Plasma or serum levels of Compound 1 are measured by LC-MS/MS at the Mass
• the solubility of Compound 1 in water is 3.8 ⁇ g/ml.
• the solubility of Compound 1 in water is 3.8 ⁇ g/ml.
• MCA middle cerebral artery occlusion
• ECA external carotid artery
• OCA internal carotid arter
• This technique is used to study a temporary occlusion in which the MCA. is blocked for one hour.
• Figure 10 shows a single slice from a T2-weighted MR image depicting the center of the brain showing cerebral cortex, hippocampus, thalamus, amygdala and hypothalamus for a "Normal" mouse (left panels) and a mouse which receives MCAo for one hour followed by 24 hours of reperfusion (right panels). Dashed lines mark the midline of the brain and show a large shift in the MC Ao brain due to cerebral edema. Solid line highlights the region of infarct in the MCAo brain.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Dermatology (AREA)
• Cardiology (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Heart & Thoracic Surgery (AREA)
• Hematology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Emergency Medicine (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Dispersion Chemistry (AREA)
• Reproductive Health (AREA)
• Pulmonology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Ophthalmology & Optometry (AREA)
• Endocrinology (AREA)
• Urology & Nephrology (AREA)

Priority Applications (6)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (1)

Family

ID=53042097

Family Applications (3)

Family Applications After (2)

Country Status (14)

Cited By (3)

Families Citing this family (5)

Citations (3)

Family Cites Families (89)

• 2014
  • 2014-11-06 CA CA2929821A patent/CA2929821A1/en active Pending
  • 2014-11-06 AU AU2014346682A patent/AU2014346682B2/en active Active
  • 2014-11-06 WO PCT/US2014/064447 patent/WO2015069961A1/en not_active Ceased
  • 2014-11-06 MX MX2016006012A patent/MX386250B/es unknown
  • 2014-11-06 CN CN202011275350.0A patent/CN112370456A/zh active Pending
  • 2014-11-06 EP EP14859359.3A patent/EP3065727B1/en active Active
  • 2014-11-06 CN CN202011275472.XA patent/CN112402434A/zh active Pending
  • 2014-11-06 EP EP14859943.4A patent/EP3065728A4/en not_active Withdrawn
  • 2014-11-06 WO PCT/US2014/064441 patent/WO2015069956A2/en not_active Ceased
  • 2014-11-06 KR KR1020167014998A patent/KR20160079109A/ko not_active Withdrawn
  • 2014-11-06 SG SG11201604153UA patent/SG11201604153UA/en unknown
  • 2014-11-06 JP JP2016552485A patent/JP2016535787A/ja not_active Ceased
  • 2014-11-06 US US15/034,543 patent/US9949991B2/en active Active
  • 2014-11-06 JP JP2016552486A patent/JP6535338B2/ja active Active
  • 2014-11-06 EP EP14860390.5A patent/EP3065729A4/en active Pending
  • 2014-11-06 RU RU2016121850A patent/RU2691951C2/ru active
  • 2014-11-06 HK HK16112696.4A patent/HK1224228A1/zh unknown
  • 2014-11-06 US US15/035,006 patent/US20160279155A1/en not_active Abandoned
  • 2014-11-06 US US15/034,274 patent/US9827253B2/en active Active
  • 2014-11-06 WO PCT/US2014/064432 patent/WO2015069948A1/en not_active Ceased
  • 2014-11-06 ES ES14859359T patent/ES2834131T3/es active Active
  • 2014-11-06 CN CN201480061066.XA patent/CN106163506A/zh active Pending
• 2016
  • 2016-05-02 IL IL245420A patent/IL245420B/en active IP Right Grant
  • 2016-05-06 MX MX2021008629A patent/MX2021008629A/es unknown
• 2017
  • 2017-10-24 US US15/792,707 patent/US10258636B2/en active Active
• 2018
  • 2018-12-31 US US16/236,817 patent/US10894055B2/en active Active
• 2019
  • 2019-05-31 JP JP2019102367A patent/JP6957557B2/ja active Active
  • 2019-10-28 US US16/665,333 patent/US11071744B2/en active Active
• 2020
  • 2020-06-01 AU AU2020203697A patent/AU2020203697A1/en not_active Abandoned
  • 2020-11-16 US US17/099,435 patent/US11801254B2/en active Active
• 2021
  • 2021-06-16 US US17/304,201 patent/US12213987B2/en active Active
  • 2021-10-06 JP JP2021164647A patent/JP2022003084A/ja active Pending
• 2023
  • 2023-10-23 US US18/492,750 patent/US12496308B2/en active Active

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events